var title_f11_50_12064="Minimum intervals between doses of recommended routine vaccines";
var content_f11_50_12064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended and minimum ages and intervals between doses of routinely recommended vaccines*",
"    <sup>",
"     &bull;",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine and dose number",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended age for this dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Minimum age for this dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended interval to next dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Minimum interval to next dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Hepatitis B",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HepB-1",
"       </td>",
"       <td>",
"        Birth",
"       </td>",
"       <td>",
"        Birth",
"       </td>",
"       <td>",
"        1-4 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HepB-2",
"       </td>",
"       <td>",
"        1-2 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        2-17 months",
"       </td>",
"       <td>",
"        8 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HepB-3",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        6-18 months",
"       </td>",
"       <td>",
"        24 weeks",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Diphtheria-tetanus-acellular pertussis",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DTaP-1",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DTaP-2",
"       </td>",
"       <td>",
"        4 months",
"       </td>",
"       <td>",
"        10 weeks",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DTaP-3",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        14 weeks",
"       </td>",
"       <td>",
"        6-12 months",
"       </td>",
"       <td>",
"        6 months",
"        <sup>",
"         &sect;&yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DTaP-4",
"       </td>",
"       <td>",
"        15-18 months",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        3 years",
"       </td>",
"       <td>",
"        6 months",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DTaP-5",
"       </td>",
"       <td>",
"        4-6 years",
"       </td>",
"       <td>",
"        4 years",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"        type b",
"        <sup>",
"         &Delta;������",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hib-1",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hib-2",
"       </td>",
"       <td>",
"        4 months",
"       </td>",
"       <td>",
"        10 weeks",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hib-3",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        14 weeks",
"       </td>",
"       <td>",
"        6-9 months",
"       </td>",
"       <td>",
"        8 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hib-4",
"       </td>",
"       <td>",
"        12-15 months",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Inactivated poliovirus",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IPV-1",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IPV-2",
"       </td>",
"       <td>",
"        4 months",
"       </td>",
"       <td>",
"        10 weeks",
"       </td>",
"       <td>",
"        2-14 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IPV-3",
"       </td>",
"       <td>",
"        6-18 months",
"       </td>",
"       <td>",
"        14 weeks",
"       </td>",
"       <td>",
"        3-5 years",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IPV-4**",
"       </td>",
"       <td>",
"        4-6 years",
"       </td>",
"       <td>",
"        4 years",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Pneumococcal conjugate",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PCV-1",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        8 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PCV-2",
"       </td>",
"       <td>",
"        4 months",
"       </td>",
"       <td>",
"        10 weeks",
"       </td>",
"       <td>",
"        8 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PCV-3",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        14 weeks",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        8 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PCV-4",
"       </td>",
"       <td>",
"        12-15 months",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Measles-mumps-rubella",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MMR-1",
"       </td>",
"       <td>",
"        12-15 months",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        3-5 years",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MMR-2",
"       </td>",
"       <td>",
"        4-6 years",
"       </td>",
"       <td>",
"        13 months",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Varicella",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Var-1",
"       </td>",
"       <td>",
"        12-15 months",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        3-5 years",
"       </td>",
"       <td>",
"        12 weeks",
"        <sup>",
"         &Delta;&Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Var-2",
"       </td>",
"       <td>",
"        4-6 years",
"       </td>",
"       <td>",
"        15 months",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Hepatitis A",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HepA-1",
"       </td>",
"       <td>",
"        12-23 months",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        6-18",
"        <sup>",
"         &sect;",
"        </sup>",
"        months",
"       </td>",
"       <td>",
"        6 months",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HepA-2",
"       </td>",
"       <td>",
"        18-41 months",
"       </td>",
"       <td>",
"        18 months",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Influenza",
"        <sup>",
"         &loz;&loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inactivated TIV",
"       </td>",
"       <td>",
"        6 months and older",
"       </td>",
"       <td>",
"        6 months",
"        <sup>",
"         &sect;&sect;",
"        </sup>",
"       </td>",
"       <td>",
"        1 month",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Live attenuated LAIV",
"       </td>",
"       <td>",
"        24 months-49 years",
"       </td>",
"       <td>",
"        24 months",
"       </td>",
"       <td>",
"        1 month",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Meningococcal conjugate MCV",
"        </strong>",
"       </td>",
"       <td>",
"        11-12 years",
"       </td>",
"       <td>",
"        2 years",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Meningococcal polysaccharide",
"        <sup>",
"         &yen;&yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MPSV-1",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        2 years",
"       </td>",
"       <td>",
"        5 years",
"       </td>",
"       <td>",
"        5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MPSV-2",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        7 years",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tetanus-diphtheria",
"        </strong>",
"        (Td)",
"       </td>",
"       <td>",
"        11-12 years",
"       </td>",
"       <td>",
"        7 years",
"       </td>",
"       <td>",
"        10 years",
"       </td>",
"       <td>",
"        5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tetanus-diphtheria-acellular pertussis",
"        </strong>",
"        Tdap",
"        <sup>",
"         ������������",
"        </sup>",
"       </td>",
"       <td>",
"        &ge;11 years",
"       </td>",
"       <td>",
"        10 years",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Pneumococcal polysaccharide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PPSV-1",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        2 years",
"       </td>",
"       <td>",
"        5 years",
"       </td>",
"       <td>",
"        5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PPSV-2",
"        <sup>",
"         ������������",
"        </sup>",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        7 years",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Human papillomavirus***",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HPV-1",
"       </td>",
"       <td>",
"        11-12 years",
"       </td>",
"       <td>",
"        9 years",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HPV-2",
"       </td>",
"       <td>",
"        11-12 years + 2 months",
"       </td>",
"       <td>",
"        109 months",
"       </td>",
"       <td>",
"        4 months",
"       </td>",
"       <td>",
"        12 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HPV-3",
"        <sup>",
"         &bull;&bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        11-12 years + 6 months",
"       </td>",
"       <td>",
"        114 months",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Rotavirus",
"        <sup>",
"         &Delta;&Delta;&Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        RV-1",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        RV-2",
"       </td>",
"       <td>",
"        4 months",
"       </td>",
"       <td>",
"        10 weeks",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        RV-3",
"        <sup>",
"         &loz;&loz;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        14 weeks",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Herpes zoster",
"        </strong>",
"        <sup>",
"         &sect;&sect;&sect;",
"        </sup>",
"       </td>",
"       <td>",
"        60 years",
"       </td>",
"       <td>",
"        60 years",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Combination vaccines are available. Use of licensed combination vaccines is generally preferred over separate injections of their equivalent component vaccines. When administering combination vaccines, the minimum age for administration is the oldest age for any of the individual components; the minimum interval between doses is equal to the greatest interval of any of the individual components.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      For travel vaccines including typhoid, Japanese encephalitis, yellow fever, see",
"      <a href=\"file://www.cdc.gov/travel\" target=\"_blank\">",
"       www.cdc.gov/travel",
"      </a>",
"      . Other vaccines that are licensed in the US but not distributed include anthrax, rhesus rotavirus and smallpox, see",
"      <a href=\"file://www.bt.cdc.gov/\" target=\"_blank\">",
"       www.bt.cdc.gov/",
"      </a>",
"      .",
"      <br>",
"       &Delta; Combination vaccines containing the Hepatitis B component are available (HepB-Hib, DTaP-HepB-IPV, and HepA-HepB). These vaccines should not be administered to infants younger than 6 weeks because of the other components (ie, Hib, DTaP, HepA, and IPV).",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Hepatitis B-3 should be administered at least 8 weeks after Hepatitis B-2 and at least 16 weeks after Hepatitis B-1, and should not be administered before age 24 weeks.",
"        <br>",
"         &sect; Calendar months.",
"         <br>",
"          &yen; The minimum recommended interval between DTaP-3 and DTaP-4 is 6 months. However, DTaP-4 need not be repeated if administered at least 4 months after DTaP-3.",
"          <br>",
"           ������ For Hib and PCV, children receiving the first dose of vaccine at age 7 months or older require fewer doses to complete the series.",
"           <br>",
"            ������ If PRP-OMP (Pedvax-Hib, Merck Vaccine Division) was administered at age 2 and 4 months, a dose at age 6 months is not required.",
"            <br>",
"             ** If the 3rd dose is given after the fourth birthday, a fourth dose is not needed.",
"             <br>",
"              <span class=\"double_bullet\">",
"               &bull;&bull;",
"              </span>",
"              Combination measles-mumps-rubella-varicella (MMRV) vaccine can be used for children aged 12 months through 12 years.",
"              <br>",
"               &Delta;&Delta; The minimum interval from VAR-1 to VAR-2 for persons beginning the series at age 13 years and older is 4 weeks.",
"               <br>",
"                <span class=\"double_lozenge\">",
"                 &loz;&loz;",
"                </span>",
"                One dose of influenza vaccine per season is recommended for most people. Children younger than 9 years of age who are receiving influenza for the first time, or received only 1 dose the previous season (if it was their first vaccination season) should receive 2 doses this season.",
"                <br>",
"                 &sect;&sect; The minimum age for inactivated influenza vaccine varies by vaccine manufacturer. Fluzone (manufactured by sanofi Pasteur) and Afluria (manufactured by Commonwealth Serum Laboratories) are approved for children 6-35 months of age. The minimum age for Fluarix (manufactured by GlaxoSmithKline) is 3 years. The minimum age for Fluvirin (manufactured by Novartis) is 4 years. For FluLaval (manufactured by GlaxoSmithKline) and Agriflu (manufactured by Novartis), the minimum age is 18 years. For Fluzone High Dose (manufactured by sanofi Pasteur) the minimum age is 65 years.",
"                 <br>",
"                  &yen;&yen; Revaccination with meningococcal vaccine is recommended for people previously vaccinated who remain at high risk of meningococcal disease.",
"                  <sup>",
"                   [1]",
"                  </sup>",
"                  <br>",
"                   ������������ Only one dose of Tdap is recommended. Subsequent doses should be given as Td. If vaccination to prevent tetanus and/or diphtheria disease is required for children aged 7 through 9 years, Td should be administered (minimum age for Td is 7 years). For one brand of Tdap, the minimum age is 11 years. The preferred interval between Tdap and a previous dose of Td is 5 years. In persons who have received a primary series of tetanus-toxoid containing vaccine, for management of a tetanus-prone wound, the minimum interval after a previous dose of any tetanus-containing vaccine is 5 years.",
"                   <br>",
"                    ������������ A second dose of PPSV is recommended 5 years after the first dose for persons at highest risk for serious pneumococcal infection and those who are likely to have a rapid decline in pneumococcal antibody concentration.",
"                    <sup>",
"                     [2]",
"                    </sup>",
"                    <br>",
"                     *** HPV2 (Cervarix, manufactured by GlaxoSmithKline) is approved for females aged 9 through 26 years. HPV4 (Gardasil, manufactured by Merck) is approved for males and females 9 through 26 years.",
"                     <br>",
"                      &bull;&bull;&bull; The minimum age for HPV-3 is based on the baseline minimum age for dose 1 (ie, 108 months) and the minimum interval of 24 weeks between the first and third dose.",
"                      <br>",
"                       &Delta;&Delta;&Delta; The first dose of RV must be administered at age 6 weeks through 14 weeks 6 days. The vaccine series should not be started at age 15 weeks 0 days or older. RV should not be administered to children older than 8 calendar months regardless of the number of doses received between 6 weeks and 8 months 0 days of age.",
"                       <br>",
"                        &loz;&loz;&loz; If two doses of Rotarix are administered as age appropriate, a third dose is not necessary.",
"                        <br>",
"                         &sect;&sect;&sect; Herpes zoster vaccine is recommended as a single dose for persons 60 years and older.",
"                        </br>",
"                       </br>",
"                      </br>",
"                     </br>",
"                    </br>",
"                   </br>",
"                  </br>",
"                 </br>",
"                </br>",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        CDC. Updated Recommendations from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at Prolonged Increased Risk for Meningococcal Disease. MMWR 2009; 58:[1042-1043].",
"       </li>",
"       <li>",
"        CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices [ACIP. MMWR 1997; 46[No. RR-8]:1-24.)",
"       </li>",
"      </ol>",
"      Centers for Diseases Control and Prevention. Available at:",
"      <a href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/A/age-interval-table.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/A/age-interval-table.pdf",
"      </a>",
"      .",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12064=[""].join("\n");
var outline_f11_50_12064=null;
var title_f11_50_12065="Remodeling postsurgery in SSc";
var content_f11_50_12065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Remodeling of metacarpal heads after resection arthroplasty in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph showing spontaneous remodeling of metacarpal heads three years after resection arthroplasty and proximal interphalangeal joint fusion. This patient with scleroderma had severe metacarpophalangeal hyperextension deformity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12065=[""].join("\n");
var outline_f11_50_12065=null;
var title_f11_50_12066="Hypertriglyceride milky plasma";
var content_f11_50_12066=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Milky plasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 246px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A milky supranatant is seen in patients with severe hypertriglyceridemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Durrington, P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12066=[""].join("\n");
var outline_f11_50_12066=null;
var title_f11_50_12067="TEE longitudinal view aortic rupture";
var content_f11_50_12067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63952%7ECARD%2F63464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63952%7ECARD%2F63464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiography longitudinal view of a traumatic rupture of the aortic isthmus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thick \"medial flap\" (arrow) was almost perpendicular to aortic walls because the injury was confined within a few centimeters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of P Vignon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiogram with color Doppler of aortic rupture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transesophageal echocardiogram with color Doppler flow mapping of aortic rupture showing similar blood flow velocities on both sides of the medial flap, and a mosaic of colors at the site of the disruption due to blood flow turbulence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of P Vignon, MD and RM Lang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12067=[""].join("\n");
var outline_f11_50_12067=null;
var title_f11_50_12068="EKG peaked T waves in hyperkalemia";
var content_f11_50_12068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    EKG showing peaked T waves in hyperkalemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 125px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A tall peaked and symmetrical T wave is the first change seen on the ECG in a patient with hyperkalemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12068=[""].join("\n");
var outline_f11_50_12068=null;
var title_f11_50_12069="Perphenazine: Patient drug information";
var content_f11_50_12069=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Perphenazine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     see \"Perphenazine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/6/10343?source=see_link\">",
"     see \"Perphenazine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Perphenazine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10012976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702720",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to perphenazine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703420",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bone marrow disease, brain problem, liver disease, or low blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11824 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12069=[""].join("\n");
var outline_f11_50_12069=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208621\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012976\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012978\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012977\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012982\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012983\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012985\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012980\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012981\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012986\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012987\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=related_link\">",
"      Perphenazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/6/10343?source=related_link\">",
"      Perphenazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_50_12070="Penicillin G benzathine: Drug information";
var content_f11_50_12070=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penicillin G benzathine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/41/44691?source=see_link\">",
"    see \"Penicillin G benzathine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/37/19029?source=see_link\">",
"    see \"Penicillin G benzathine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7272304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bicillin&reg; L-A",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bicillin&reg; L-A",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     I.M.: 1.2-2.4 million units as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Upper respiratory infection, group A streptococci:",
"     </b>",
"     1.2 million units as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Secondary prevention of glomerulonephritis:",
"     </i>",
"     1.2 million units every 4 weeks or 600,000 units twice monthly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Secondary prevention of rheumatic fever:",
"     </i>",
"     1.2 million units every 3-4 weeks or 600,000 units twice monthly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pharyngitis, group A streptococci (IDSA guidelines):",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Acute treatment:",
"     </i>",
"     1.2 million units as a single dose (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Chronic carrier treatment:",
"     </i>",
"     1.2 million units as a single dose in combination with oral rifampin (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Syphilis (CDC, 2010):",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Primary, Secondary, Early Latent (&lt;1 year duration):",
"     </i>",
"     2.4 million units as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Late Latent, Latent with unknown duration:",
"     </i>",
"     2.4 million units once weekly for 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Neurosyphilis:",
"     </i>",
"     Not indicated as single-drug therapy, but may be given once weekly for 3 weeks following I.V. treatment; refer to Penicillin G Parenteral/Aqueous monograph for dosing",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F207591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/37/19029?source=see_link\">",
"      see \"Penicillin G benzathine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     I.M.: 25,000-50,000 units/kg as a single dose (maximum: 2.4 million units)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Upper respiratory infection, group A streptococci:",
"     </b>",
"     Infants and Children: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Primary prevention of rheumatic fever (Gerber, 2009):",
"     </i>",
"     &le;27 kg: 600,000 units as a single dose; &gt;27 kg: 1.2 million units as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Secondary prevention of rheumatic fever (Gerber, 2009):",
"     </i>",
"     &le;27 kg: 600,000 units every 3-4 weeks; &gt;27 kg: 1.2 million units every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pharyngitis, group A streptococci (IDSA guidelines):",
"     </b>",
"     Infants and Children: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Acute treatment:",
"     </i>",
"     &lt;27 kg: 600,000 units as a single dose; &ge;27 kg: 1.2 million units as a single dose (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Chronic carrier treatment:",
"     </i>",
"     &lt;27 kg: 600,000 units as a single dose (in combination with oral rifampin); &ge;27 kg: 1.2 million units as a single dose (in combination with oral rifampin) (Shulman, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Syphilis (CDC, 2010):",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Primary, Secondary, Early Latent (&lt;1 year duration):",
"     </i>",
"     Infants and Children: 50,000 units/kg as a single injection (maximum: 2.4 million units)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Late Latent, Latent with unknown duration:",
"     </i>",
"     Children: 50,000 units/kg every week for 3 doses (maximum: 2.4 million units/dose)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F207575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bicillin&reg; L-A: 600,000 units/mL (1 mL, 2 mL, 4 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F207556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Warm to room temperature before administration to lessen the pain associated with injection. Administer by deep I.M. injection in the upper outer quadrant of the buttock; in children &lt;2 years of age, I.M. injections should be made into the midlateral muscle of the thigh, not the gluteal region. Do not inject near an artery or a nerve; permanent neurological damage or gangrene may result.  When doses are repeated, rotate the injection site.",
"     <b>",
"      Do not administer I.V., intra-arterially, or SubQ.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active against some gram-positive organisms, few gram-negative organisms such as",
"     <i>",
"      Neisseria gonorrhoeae",
"     </i>",
"     , and some anaerobes and spirochetes; used in the treatment of syphilis; used only for the treatment of mild to moderately-severe upper respiratory tract infections caused by organisms susceptible to low concentrations of penicillin G or for prophylaxis of infections caused by these organisms; primary and secondary prevention of rheumatic fever",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Penicillin may be confused with penicillamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bicillin&reg; may be confused with Wycillin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Penicillin G benzathine may only be administered by deep intramuscular injection; intravenous administration of penicillin G benzathine has been associated with cardiopulmonary arrest and death.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bicillin&reg; C-R (penicillin G benzathine and penicillin G procaine) may be confused with Bicillin&reg; L-A (penicillin G benzathine). Penicillin G benzathine is the only product currently approved for the treatment of syphilis. Administration of penicillin G benzathine and penicillin G procaine combination instead of Bicillin&reg; L-A may result in inadequate treatment response.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, cerebral vascular accident, cyanosis, gangrene, hypotension, pallor, palpitations, syncope, tachycardia, vasodilation, vasospasm, vasovagal reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, coma, confusion, dizziness, euphoria, fatigue, headache, nervousness, pain, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     In addition, a syndrome of CNS symptoms has been reported which includes: Severe agitation with confusion, hallucinations (auditory and visual), and fear of death (Hoigne&rsquo;s syndrome); other symptoms include cyanosis, dizziness, palpitations, psychosis, seizures, tachycardia, taste disturbance, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bloody stool, intestinal necrosis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, priapism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions: Abscess, atrophy, bruising, cellulitis, edema, hemorrhage, inflammation, lump, necrosis, pain, skin ulcer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis exacerbation, joint disorder, neurovascular damage, numbness, periostitis, rhabdomyolysis, transverse myelitis, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blindness, blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, hematuria, myoglobinuria, neurogenic bladder, proteinuria, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, hypersensitivity reactions, Jarisch-Herxheimer reaction, lymphadenopathy, mottling, warmth",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F207559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to penicillin(s) or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F207541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syphilis/neurosyphilis use: CDC and AAP do not currently recommend the use of penicillin G benzathine to treat congenital syphilis or neurosyphilis due to reported treatment failures and lack of published clinical data on its efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration:",
"     <b>",
"      [U.S. Boxed Warning]: Not for intravenous use; cardiopulmonary arrest and death have occurred from inadvertent I.V. administration.",
"     </b>",
"     Administer by deep I.M. injection only. Injection into or near an artery or nerve could result in severe neurovascular damage or permanent neurological damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Penicillin crosses the placenta and distributes into amniotic fluid. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Penicillin G is the drug of choice for treatment of syphilis during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F207578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5694831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Penicillins are excreted in breast milk. The manufacturer recommends that caution be exercised when administering penicillin to nursing women.  Nondose-related effects could include modification of bowel flora and allergic sensitization.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F207561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Bicillin L-A Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600000 units/mL (1 mL): $42.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200000 units/2 mL (2 mL): $73.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2400000 units/4 mL (4 mL): $150.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F207551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for signs and symptoms of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F207562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Benzetacil (BR, EC, ES, MX);",
"     </li>",
"     <li>",
"      Benzetacil L.A. (AR, CO, PE, PY, UY, VE);",
"     </li>",
"     <li>",
"      Bicillin L-A (AU, NZ);",
"     </li>",
"     <li>",
"      Bicillin LA 1.2 (ZA);",
"     </li>",
"     <li>",
"      Bicillin LA 2.4 (ZA);",
"     </li>",
"     <li>",
"      Biconcilina BZ (EC);",
"     </li>",
"     <li>",
"      Brevicilina (ES);",
"     </li>",
"     <li>",
"      Cepacilina (ES);",
"     </li>",
"     <li>",
"      Debecylina (PL);",
"     </li>",
"     <li>",
"      Diaminocillina (IT);",
"     </li>",
"     <li>",
"      Extencilline (FR, HR);",
"     </li>",
"     <li>",
"      Lentocilin-S (PT);",
"     </li>",
"     <li>",
"      Leomypen (DK);",
"     </li>",
"     <li>",
"      LPG (AU);",
"     </li>",
"     <li>",
"      Pan-Benzathine Pen G (HK);",
"     </li>",
"     <li>",
"      Pen Di Ben (AR, CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Penadur (CH, LU);",
"     </li>",
"     <li>",
"      Penadur - LA (BB, BM, BS, BZ, GY, JM, PR, SR, TT);",
"     </li>",
"     <li>",
"      Penadur L.A. (BE, GR, PT);",
"     </li>",
"     <li>",
"      Penadur LA (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Pendepon (CZ);",
"     </li>",
"     <li>",
"      Pendysin (DE);",
"     </li>",
"     <li>",
"      Penidural (NL);",
"     </li>",
"     <li>",
"      Penidure LA 12 (IN);",
"     </li>",
"     <li>",
"      Penidure LA 24 (IN);",
"     </li>",
"     <li>",
"      Penidure LA 6 (IN);",
"     </li>",
"     <li>",
"      Penilente (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Peniroger Retard (ES);",
"     </li>",
"     <li>",
"      Penretard (BR);",
"     </li>",
"     <li>",
"      Pisaben L-A (EC);",
"     </li>",
"     <li>",
"      Provipen Benzatina (ES);",
"     </li>",
"     <li>",
"      Retarpen (AE, AT, BH, CY, CZ, EG, HR, IL, IQ, IR, JO, KW, LB, LY, MY, OM, PL, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Tardocillin (DE);",
"     </li>",
"     <li>",
"      Taropen (PL);",
"     </li>",
"     <li>",
"      Unicil (CO);",
"     </li>",
"     <li>",
"      Wycillina A P (IT);",
"     </li>",
"     <li>",
"      Zalpen (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F207540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial cell wall synthesis during active multiplication, causing cell wall death and resultant bactericidal activity against susceptible bacteria",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F207558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 1-4 weeks (dose dependent); larger doses result in more sustained levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Highest levels in the kidney; lesser amounts in liver, skin, intestines",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein Binding: ~60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 12-24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-207. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Adult_OI_041009.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Adult_OI_041009.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12070/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Sexually Transmitted Diseases Treatment Guidelines, 2006,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 55(RR-11):1-94.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12070/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Collart P, Poitevin M, Milovanovic A, et al, &ldquo;Kinetic Study of Serum Penicillin Concentrations After Single Doses of Benzathine and Benethamine Penicillins in Young and Old People,&rdquo;",
"      <i>",
"       Br J Vener Dis",
"      </i>",
"      , 1980, 56(6):355-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12070/abstract-text/7448577/pubmed\" id=\"7448577\" target=\"_blank\">",
"        7448577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al, &ldquo;Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(11):1541-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12070/abstract-text/19246689/pubmed\" id=\"19246689\" target=\"_blank\">",
"        19246689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12070/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan EL, Berrios X, Speth J, et al, &ldquo;Pharmacokinetics of Benzathine Penicillin G: Serum Levels During the 28 Days After Intramuscular Injection of 1,200,000 Units,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 115(1):146-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12070/abstract-text/2738782/pubmed\" id=\"2738782\" target=\"_blank\">",
"        2738782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 55(10):e86-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12070/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9551 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12070=[""].join("\n");
var outline_f11_50_12070=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7272304\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207570\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663226\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207608\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207574\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207591\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207575\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207553\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207537\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207556\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207554\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207616\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207606\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207559\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207541\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299839\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207546\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207549\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720604\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207578\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5694831\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207561\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207551\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207562\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207540\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207558\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9551\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9551|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/41/44691?source=related_link\">",
"      Penicillin G benzathine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/37/19029?source=related_link\">",
"      Penicillin G benzathine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_50_12071="Approach to imaging modalities in the setting of suspected osteomyelitis";
var content_f11_50_12071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to imaging modalities in the setting of suspected osteomyelitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/50/12071/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/50/12071/contributors\">",
"     Mary Hochman, MD, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/50/12071/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/50/12071/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/50/12071/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/50/12071/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/50/12071/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging can be a useful tool in the setting of suspected osteomyelitis, particularly for supporting a presumed clinical diagnosis, delineating the extent of disease, and planning therapy (",
"    <a class=\"graphic graphic_table graphicRef61072 \" href=\"UTD.htm?4/43/4796\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, interpretation of imaging findings can be a diagnostic challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/1\">",
"     1",
"    </a>",
"    ]. The sensitivity of radiographs for detecting of acute osteomyelitis is limited. MRI and nuclear medicine studies can have limited specificity in the setting of confounding bony pathology, although both have high negative predictive value for osteomyelitis.",
"   </p>",
"   <p>",
"    The benefits and limitations of radiographs, magnetic resonance imaging (MRI), computed tomography (CT), nuclear modalities, and ultrasonography for the diagnosis of osteomyelitis will be reviewed here. An integrated diagnostic approach including radiography together with other clinical data for the diagnosis of osteomyelitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of osteomyelitis in adults\", section on 'Suggested diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of osteomyelitis, inflammatory exudate in the marrow leads to increased intramedullary pressure, with subsequent extension of exudate into the bone cortex where it can rupture through to the periosteum. If this occurs, the periosteal blood supply to the bone is interrupted, leading to necrosis. The resulting fragments of isolated dead bone (known as sequestra) can be visualized radiographically.",
"   </p>",
"   <p>",
"    Acute osteomyelitis refers to infection in the bone prior to development of sequestra. In some forms of infection, development of sequestra is relatively slow (such as vertebral osteomyelitis), while in others the development of sequestra occurs relatively rapidly (such as osteomyelitis in the setting of prosthetic devices or compound fractures) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/1\">",
"     1",
"    </a>",
"    ]. Following formation of sequestra, the infection is considered chronic osteomyelitis. Other hallmarks of chronic osteomyelitis include involucrum (reactive bony encasement of the sequestrum), local bone loss, and sinus tracts (extension of infection through cortical bone).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RADIOGRAPHS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional radiographs are relatively inexpensive and readily available; they may suggest a diagnosis of osteomyelitis, exclude other pathology, or provide clues for other conditions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82657 \" href=\"UTD.htm?14/31/14833\">",
"     image 1",
"    </a>",
"    ). Radiographs can be useful for demonstrating findings of chronic osteomyelitis; characteristic findings include cortical erosion, periosteal reaction, mixed lucency, and sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Other findings may include sequestra (devitalized bone with radiodense appearance) and soft tissue swelling (particularly when osteomyelitis is accompanied by cellulitis or abscess). In the setting of orthopedic hardware, findings of osteomyelitis may include fracture nonunion or periprosthetic lucency indicative of hardware loosening.",
"   </p>",
"   <p>",
"    Radiographs are limited by their sensitivity and specificity (in one review of 140 cases, 14 and 70 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/4\">",
"     4",
"    </a>",
"    ]. This is particularly true in early infection, when imaging findings may be subtle or radiographically absent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53313 \" href=\"UTD.htm?7/46/7905\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/5\">",
"     5",
"    </a>",
"    ]. While nonspecific soft tissue changes can be seen as early as three days, osseous changes attributable to osteomyelitis may not be visible on radiographs in the first one to two weeks of infection. The earliest osseous change may simply be regional osteopenia, a subtle and non-specific finding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, radiography may be insufficient to distinguish osteomyelitis from other processes such as Charcot arthropathy and, on occasion, fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/7\">",
"     7",
"    </a>",
"    ]. Following trauma, radiographic findings of architectural distortion, osteopenia due to disuse, and normal fracture healing may be difficult to distinguish from osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MAGNETIC RESONANCE IMAGING (MRI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is very sensitive for the detection of acute osteomyelitis and demonstrates abnormal marrow edema as early as three to five days following onset of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. It is the best modality available for obtaining detailed images delineating the extent of cortical destruction characteristic of osteomyelitis as well as bone marrow and soft tissue inflammation (such as in the setting of cellulitis or myositis) (",
"    <a class=\"graphic graphic_picture graphicRef80488 \" href=\"UTD.htm?25/10/25764\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. While these findings can be demonstrated on non-contrast-enhanced images, gadolinium contrast-enhanced MRI is useful for demonstrating features such as sinus tracts, fistulas, and abscesses. It should be noted, however, that because of concerns linking some gadolinium-based contrast agents to the disease nephrogenic systemic fibrosis (NSF) in patients with severely impaired renal function, the FDA now recommends screening patients for renal function prior to administration of a gadolinium-based contrast agent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In light of its sensitivity, MRI also has a high negative predictive value for osteomyelitis: an MRI with no evidence for osteomyelitis is typically viewed as good evidence for having excluded osteomyelitis if clinical signs or symptoms have been present for &ge;1 week [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/1\">",
"     1",
"    </a>",
"    ]. The sensitivity of MRI is similar to that of radionuclide studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although MRI is sensitive for detection of bone marrow edema associated with osteomyelitis, a bone marrow edema pattern on MRI is a nonspecific finding that can also be seen with a variety of different pathologies, such as contusion, fracture, postsurgical change, Charcot arthropathy, osteonecrosis, adjacent arthritis, or neoplasm. Thus, given the extensive differential diagnosis of a bone marrow edema pattern, establishing the correct diagnosis depends on the clinical setting and on any additional imaging findings. Moreover, if infection co-exists with additional pathology that can cause a bone marrow edema pattern, MRI cannot reliably distinguish between marrow changes attributable to infection and those attributable to other pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, MRI may overestimate both the extent and duration of infection. Reactive marrow edema may co-exist with true marrow infection, leading to an imaging abnormality that is larger than the area of actual infection. Bone marrow changes may also persist for weeks to months after osteomyelitis begins to respond to therapy. Such findings can lead to more aggressive treatment than necessary.",
"   </p>",
"   <p>",
"    MRI is especially useful for evaluation of osteomyelitis in the foot (particularly in the setting of diabetes) and in the vertebrae (given its excellent depiction of the adjacent spinal cord).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRI is the preferred modality for evaluation of osteomyelitis in the setting of diabetic foot ulcers (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57504 \" href=\"UTD.htm?33/19/34100\">",
"       image 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/5,16\">",
"       5,16",
"      </a>",
"      ]. This was illustrated in a meta-analysis of 16 studies in which MRI was superior to radiographs, three phase technetium bone scanning, and white blood cell scanning.",
"     </li>",
"     <li>",
"      MRI is the modality of choice for delineating the anatomy of the spinal cord and the adjacent osseous and soft tissues. In vertebral osteomyelitis, findings on T1-weighted images include decreased signal intensity in the disk and adjacent vertebral bodies and loss of endplate definition [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/17\">",
"       17",
"      </a>",
"      ]. Findings on T2-weighted images include increased signal intensity in the disk and adjacent vertebral bodies. Following intravenous administration of gadolinium, there is enhancement of the disk, adjacent vertebral bodies, and involved paraspinal and epidural soft tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=see_link\">",
"       \"Vertebral osteomyelitis and discitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients may not be candidates for MRI, including those with cardiac pacemakers, implanted insulin pumps, or other devices. Even some metallic implants that are MRI-compatible may obscure a region of interest due to metallic susceptibility artifact, if the metal lies near a site of suspected infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMPUTED TOMOGRAPHY (CT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is the modality of choice in circumstances where MRI imaging cannot be obtained. CT is useful for assessing cortical and trabecular integrity, periosteal reaction, intraosseous gas, and the extent of sinus tracts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78389 \" href=\"UTD.htm?33/57/34707\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/5,8,19-22\">",
"     5,8,19-22",
"    </a>",
"    ]. It is the most useful modality to evaluate for presence of osseous sequestra, and it can provide excellent anatomic delineation of adjacent soft tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, as with MRI, metallic hardware can give rise to artifact that may degrade image quality and limit diagnostic capability (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67235 \" href=\"UTD.htm?33/27/34228\">",
"     image 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NUCLEAR MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuclear imaging can be a useful diagnostic alternative to MRI, although the findings must be interpreted with caution. Nuclear imaging tends to be more reliable for evaluation of acute infection than chronic infection given its sensitivity for detecting evidence of inflammation.",
"   </p>",
"   <p>",
"    The most common nuclear imaging studies used in the assessment of osteomyelitis are the three phase bone scan, gallium scan, and tagged white blood cell scan. Bone marrow scans are less commonly used for this purpose. Scans utilizing radiolabeled antigranulocyte antibodies and radiolabeled antibiotics have not yet entered routine clinical practice. Flourine-18 labeled fluorodeoxyglucose (FDG) imaging using positron emission tomography (PET) has shown promising early results for imaging of infection, but remains an investigational technique for this application [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Three phase bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three phase bone scans use a radionuclide tracer that accumulates in areas of bone turnover and increased osteoblast activity (such as technetium-99m bound to a phosphorus containing compound) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/25\">",
"     25",
"    </a>",
"    ]. Scans are performed using a gamma camera at three points following tracer injection: immediately after injection (blood flow phase), 15 minutes after injection (blood pool phase), and four hours after injection (osseous phase). In the setting of osteomyelitis, there is intense uptake in all three phases. In contrast, in the setting of cellulitis there is increased activity only in the first two phases and normal or mild diffuse increased activity in the third phase [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity and specificity of three phase bone scan for detection of osteomyelitis varies depending on the appearance of correlative radiographs. If radiographs are normal, three phase bone scan has a sensitivity and specificity of about 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/1,25,26\">",
"     1,25,26",
"    </a>",
"    ]. If radiographs demonstrate noninfectious disorders such as fracture or Charcot arthropathy, entities associated with bone formation, and radionuclide tracer uptake, false-positive results are more likely. False-negative results are possible in early osteomyelitis or in the setting of chronic osteomyelitis with impaired blood flow or infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gallium and dual tracer scans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallium scans utilize the affinity of gallium-67 to acute phase reactants (lactoferrin, transferrin, and others) to demonstrate areas of inflammation that may be related to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/28\">",
"     28",
"    </a>",
"    ]. This method is quite sensitive and more specific than three phase bone scan (sensitivity and specificity 25 to 80 and 67 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. If negative, gallium scans effectively exclude the diagnosis of osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/1\">",
"     1",
"    </a>",
"    ]. False-positive results can occur in the setting of uptake related to fracture and neoplasm; correlative radiographs may help to evaluate for these entities.",
"   </p>",
"   <p>",
"    Gallium scanning is typically performed 24 hours following injection and therefore should be reserved for patients who are clinically stable and do not require prompt imaging results for urgent management decisions.",
"   </p>",
"   <p>",
"    A gallium scan can be performed concurrently with a technetium labeled three phase bone scan, and the information gathered may be more useful than that obtained from either examination alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/30\">",
"     30",
"    </a>",
"    ]. In this instance, both radionuclide species are injected at the same time. Then, bone scan images can be obtained three to four hours after injection, and gallium scan images can be obtained up to 24 hours later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tagged white blood cell scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tagged white blood cell (WBC) scan uses autologous WBCs labeled with indium 111 oxyquinoline, gallium-67, or technetium-99m [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/1\">",
"     1",
"    </a>",
"    ]. To perform the study, blood is drawn from the patient, and the white blood cells are separated for labeling with tracer; after a few hours, the tagged white cells are returned to the patient's circulation via intravenous injection. Images are taken up to 24 hours later. The tagged white cells accumulate in the bone marrow and at sites of inflammation or infection; they are not specific for bone.",
"   </p>",
"   <p>",
"    Tagged WBC scans are similar in sensitivity to bone scans for evaluation of osteomyelitis, but the specificity can be poor if corresponding radiographs are not normal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/28\">",
"     28",
"    </a>",
"    ]. Additionally, regions with substantial quantities of red marrow (such as the vertebral bodies) are not visualized reliably with this modality; WBC scans may best be used in the distal extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/27\">",
"     27",
"    </a>",
"    ]. Tagged WBC scans can be falsely positive in the setting of other causes of inflammation including fracture and Charcot arthropathy. False-negative results are possible in the setting of chronic osteomyelitis when white cell migration to sites of infection is decreased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Limitations of nuclear imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major limitation of these modalities is that radiographic evidence of bone turnover or inflammation due to noninfectious bone pathology may be confused with osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Such conditions include recent trauma or surgery, recently healed osteomyelitis, septic arthritis, degenerative joint disease, bone tumors, Paget disease, and other noninfectious inflammatory bone conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]. False-negative results are possible in areas of relative ischemia (a common comorbidity in osteomyelitis) since radiotracer may not be adequately delivered to the target site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ULTRASONOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound may be a useful diagnostic tool in circumstances where other modalities are not readily available. Typically, bone is not well depicted by ultrasound, because the cortical surface of the bone reflects the acoustic energy that is used to generate ultrasound images. However, changes superficial to cortical bone can be visualized by ultrasound.",
"   </p>",
"   <p>",
"    Thus, in osteomyelitis, ultrasound can demonstrate elevation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thickening of the periosteum due to pus emanating from the bone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Ultrasound may be more useful for detection of these findings in pediatric patients, since the periosteum in the immature skeleton is more loosely adherent to the cortex than in the adult skeleton [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/1\">",
"     1",
"    </a>",
"    ]. Ultrasonography is considered excellent for evaluation of suspected osteomyelitis in the setting of sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12071/abstract/38\">",
"     38",
"    </a>",
"    ]. Ultrasound may also be useful in providing guidance for needle biopsies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUGGESTED APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of imaging for evaluation of suspected osteomyelitis must be combined with the clinical presentation, culture data, and laboratory results. A suggested diagnostic approach incorporating all of these factors is outlined in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of osteomyelitis in adults\", section on 'Suggested diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiographs are of limited sensitivity and specificity in the detection of acute osteomyelitis. Bone findings such as osteolysis and periosteal new bone formation may not be evident until 10 to 14 days following onset of infection. Radiographs are particularly useful for demonstrating findings of chronic osteomyelitis; these may include cortical erosion, periosteal reaction, mixed bony lucency and sclerosis, and sequestra. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) is the best modality for obtaining detailed anatomic delineation of the extent of bone marrow and soft tissue inflammation. It is especially useful for evaluation of osteomyelitis in the foot (particularly in the setting of diabetes) and in the vertebrae (given its excellent depiction of the spinal cord and associated structures). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Magnetic resonance imaging (MRI)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone marrow edema on MRI is not specific for osteomyelitis, and, in the absence of secondary findings such as contiguity with an infected ulcer, MRI cannot effectively distinguish osteomyelitis from other causes of marrow edema, such as contusion, Charcot, or recent postsurgical changes. MRI may also overestimate the extent of infection, since marrow edema due to osteomyelitis and surrounding reactive edema cannot be distinguished. Moreover, marrow edema may persist even in the setting of successful response to treatment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Magnetic resonance imaging (MRI)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography (CT) can provide excellent anatomic delineation of areas involved by infection, and it is the modality of choice in circumstances where MRI imaging cannot be obtained. However, as with MRI, metal hardware may limit the use of CT. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Computed tomography (CT)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nuclear imaging is a reasonable diagnostic choice in circumstances where MRI or CT images cannot be obtained. The most common nuclear imaging studies are three phase bone scans, gallium and dual tracer scans, and tagged white blood cell scans. Nuclear imaging findings must be interpreted with caution; the major limitation of these modalities is that radionuclide evidence of bone turnover or inflammation due to noninfectious bone pathology may be confused with osteomyelitis. Also, false-negative studies may occur when blood flow to the affected area is diminished. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nuclear modalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound may be a useful diagnostic tool in circumstances where the more preferred modalities are not readily available. In addition, ultrasound is excellent for evaluation of suspected osteomyelitis in the setting of sickle cell disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"       \"Overview of the clinical manifestations of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of imaging for evaluation of suspected osteomyelitis must be combined with the clinical presentation and additional diagnostic information. A suggested diagnostic approach incorporating all of these factors is outlined in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of osteomyelitis in adults\", section on 'Suggested diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347188781\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Perry Horwich, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/1\">",
"      Pineda C, Vargas A, Rodr&iacute;guez AV. Imaging of osteomyelitis: current concepts. Infect Dis Clin North Am 2006; 20:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/2\">",
"      Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/3\">",
"      Darouiche RO, Landon GC, Klima M, et al. Osteomyelitis associated with pressure sores. Arch Intern Med 1994; 154:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/4\">",
"      Tumeh SS, Aliabadi P, Weissman BN, McNeil BJ. Disease activity in osteomyelitis: role of radiography. Radiology 1987; 165:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/5\">",
"      Gold RH, Hawkins RA, Katz RD. Bacterial osteomyelitis: findings on plain radiography, CT, MR, and scintigraphy. AJR Am J Roentgenol 1991; 157:365.",
"     </a>",
"    </li>",
"    <li>",
"     Bone and Joint Imaging, 3rd ed, Resnick D, Kransdorf M (Eds), Elsevier, Philadelphia 2005. p.718.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/7\">",
"      Kaim AH, Gross T, von Schulthess GK. Imaging of chronic posttraumatic osteomyelitis. Eur Radiol 2002; 12:1193.",
"     </a>",
"    </li>",
"    <li>",
"     Berbari EF, Steckelberg JM, Osmon DR. Osteomyelitis. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, et al (Eds), Elsevier, Philadelphia 2005. p.1322.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/9\">",
"      Butalia S, Palda VA, Sargeant RJ, et al. Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA 2008; 299:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/10\">",
"      Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. Clin Infect Dis 2008; 47:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/11\">",
"      Erdman WA, Tamburro F, Jayson HT, et al. Osteomyelitis: characteristics and pitfalls of diagnosis with MR imaging. Radiology 1991; 180:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/12\">",
"      Durham JR, Lukens ML, Campanini DS, et al. Impact of magnetic resonance imaging on the management of diabetic foot infections. Am J Surg 1991; 162:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/13\">",
"      Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008; 248:799.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Gadolinium-based Contrast Agents: Class Labeling Change - Risk of Nephrogenic Systemic Fibrosis. Available at: file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm225375.htm (Accessed on August 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/15\">",
"      Tomas MB, Patel M, Marwin SE, Palestro CJ. The diabetic foot. Br J Radiol 2000; 73:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/16\">",
"      Kapoor A, Page S, Lavalley M, et al. Magnetic resonance imaging for diagnosing foot osteomyelitis: a meta-analysis. Arch Intern Med 2007; 167:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/17\">",
"      Karchevsky M, Schweitzer ME, Morrison WB, Parellada JA. MRI findings of septic arthritis and associated osteomyelitis in adults. AJR Am J Roentgenol 2004; 182:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/18\">",
"      Dagirmanjian A, Schils J, McHenry M, Modic MT. MR imaging of vertebral osteomyelitis revisited. AJR Am J Roentgenol 1996; 167:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/19\">",
"      Ledermann HP, Kaim A, Bongartz G, Steinbrich W. Pitfalls and limitations of magnetic resonance imaging in chronic posttraumatic osteomyelitis. Eur Radiol 2000; 10:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/20\">",
"      Mader JT, Ortiz M, Calhoun JH. Update on the diagnosis and management of osteomyelitis. Clin Podiatr Med Surg 1996; 13:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/21\">",
"      Wing VW, Jeffrey RB Jr, Federle MP, et al. Chronic osteomyelitis examined by CT. Radiology 1985; 154:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/22\">",
"      Seltzer SE. Value of computed tomography in planning medical and surgical treatment of chronic osteomyelitis. J Comput Assist Tomogr 1984; 8:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/23\">",
"      Keidar Z, Militianu D, Melamed E, et al. The diabetic foot: initial experience with 18F-FDG PET/CT. J Nucl Med 2005; 46:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/24\">",
"      Chacko TK, Zhuang H, Nakhoda KZ, et al. Applications of fluorodeoxyglucose positron emission tomography in the diagnosis of infection. Nucl Med Commun 2003; 24:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/25\">",
"      Schauwecker DS. The scintigraphic diagnosis of osteomyelitis. AJR Am J Roentgenol 1992; 158:9.",
"     </a>",
"    </li>",
"    <li>",
"     Schauwecker DS. The role of nuclear medicine in osteomyelitis. In: Skeletal Nuclear Medicine, Collier DB, et al (Eds), Mosby, St. Louis 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/27\">",
"      Schauwecker DS. Osteomyelitis: diagnosis with In-111-labeled leukocytes. Radiology 1989; 171:141.",
"     </a>",
"    </li>",
"    <li>",
"     Thrall J, Ziessman H. Nuclear Medicine: The Requisites, 2nd ed, Mosby, St. Louis 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/29\">",
"      Palestro CJ, Kim CK, Swyer AJ, et al. Radionuclide diagnosis of vertebral osteomyelitis: indium-111-leukocyte and technetium-99m-methylene diphosphonate bone scintigraphy. J Nucl Med 1991; 32:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/30\">",
"      Tumeh SS, Aliabadi P, Weissman BN, McNeil BJ. Chronic osteomyelitis: bone and gallium scan patterns associated with active disease. Radiology 1986; 158:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/31\">",
"      Gross T, Kaim AH, Regazzoni P, Widmer AF. Current concepts in posttraumatic osteomyelitis: a diagnostic challenge with new imaging options. J Trauma 2002; 52:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/32\">",
"      Al-Sheikh W, Sfakianakis GN, Mnaymneh W, et al. Subacute and chronic bone infections: diagnosis using In-111, Ga-67 and Tc-99m MDP bone scintigraphy, and radiography. Radiology 1985; 155:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/33\">",
"      Kaim A, Maurer T, Ochsner P, et al. Chronic complicated osteomyelitis of the appendicular skeleton: diagnosis with technetium-99m labelled monoclonal antigranulocyte antibody-immunoscintigraphy. Eur J Nucl Med 1997; 24:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/34\">",
"      Kolindou A, Liu Y, Ozker K, et al. In-111 WBC imaging of osteomyelitis in patients with underlying bone scan abnormalities. Clin Nucl Med 1996; 21:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/35\">",
"      Abiri MM, Kirpekar M, Ablow RC. Osteomyelitis: detection with US. Radiology 1989; 172:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/36\">",
"      Howard CB, Einhorn M, Dagan R, Nyska M. Ultrasound in diagnosis and management of acute haematogenous osteomyelitis in children. J Bone Joint Surg Br 1993; 75:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/37\">",
"      Wheat J. Diagnostic strategies in osteomyelitis. Am J Med 1985; 78:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12071/abstract/38\">",
"      Booz MM, Hariharan V, Aradi AJ, Malki AA. The value of ultrasound and aspiration in differentiating vaso-occlusive crisis and osteomyelitis in sickle cell disease patients. Clin Radiol 1999; 54:636.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7653 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12071=[""].join("\n");
var outline_f11_50_12071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RADIOGRAPHS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MAGNETIC RESONANCE IMAGING (MRI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMPUTED TOMOGRAPHY (CT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NUCLEAR MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Three phase bone scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gallium and dual tracer scans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tagged white blood cell scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Limitations of nuclear imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ULTRASONOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUGGESTED APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H347188781\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7653\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7653|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/31/14833\" title=\"diagnostic image 1\">",
"      Toe osteo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/46/7905\" title=\"diagnostic image 2\">",
"      Early osteo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/19/34100\" title=\"diagnostic image 3\">",
"      Osteo diabetic foot ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/57/34707\" title=\"diagnostic image 4\">",
"      Osteomyelitis in heel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/27/34228\" title=\"diagnostic image 5\">",
"      Osteo in hip prosthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7653|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/10/25764\" title=\"picture 1\">",
"      Osteo in patella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7653|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/43/4796\" title=\"table 1\">",
"      Dx osteo diabetic foot",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=related_link\">",
"      Vertebral osteomyelitis and discitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_50_12072="Mycophenolate: Pediatric drug information";
var content_f11_50_12072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mycophenolate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"    see \"Mycophenolate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/56/22406?source=see_link\">",
"    see \"Mycophenolate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CellCept&reg;;",
"     </li>",
"     <li>",
"      Myfortic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F198687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Mycophenolate;",
"     </li>",
"     <li>",
"      CellCept&reg;;",
"     </li>",
"     <li>",
"      CO Mycophenolate;",
"     </li>",
"     <li>",
"      JAMP-Mycophenolate;",
"     </li>",
"     <li>",
"      Myfortic&reg;;",
"     </li>",
"     <li>",
"      Mylan-Mycophenolate;",
"     </li>",
"     <li>",
"      Novo-Mycophenolate;",
"     </li>",
"     <li>",
"      Sandoz-Mycophenolate;",
"     </li>",
"     <li>",
"      Sandoz-Mycophenolate Mofetil",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immunosuppressant Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"      see \"Mycophenolate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Mycophenolate mofetil (CellCept&reg;) tablets, capsules, and suspension should",
"     <b>",
"      not",
"     </b>",
"     be interchanged with the delayed-release tablet formulation (Myfortic&reg;) due to differences in the rate of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mycophenolate mofetil: I.V., Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Renal transplantation (",
"     <b>",
"      Note:",
"     </b>",
"     If using I.V. route, administer within 24 hours following transplantation; can be given for up to 14 days; patients should be switched to oral formulation as soon as oral medication is tolerated): 600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily; maximum dose: 2 g/day;",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetic studies suggest that doses of mycophenolate adjusted to body surface area resulted in AUCs which better approximated those of adults versus doses adjusted for body weight which resulted in lower AUCs in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     BSA 1.25 m",
"     <sup>",
"      2",
"     </sup>",
"     to 1.5 m",
"     <sup>",
"      2",
"     </sup>",
"     : 750 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     BSA &gt;1.5 m",
"     <sup>",
"      2",
"     </sup>",
"     : 1 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Nephrotic syndrome:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Frequently relapsing: 12.5-18 mg/kg/dose twice daily; maximum dose: 2 g/day for 1-2 years with a tapering dose of prednisone (Gipson, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Steroid-dependent (secondary in the setting of glucocorticoid toxicity): 12-18 mg/kg/dose or 600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily; maximum dose: 2 g/day (Gipson, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mycophenolate delayed-release tablet: Oral: Renal tranplantation: 400-450 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily; maximum dose: 720 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     BSA &lt;1.19 m",
"     <sup>",
"      2",
"     </sup>",
"     : Use of this formulation is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     BSA 1.19-1.58 m",
"     <sup>",
"      2",
"     </sup>",
"     : 540 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     BSA &gt;1.58 m",
"     <sup>",
"      2",
"     </sup>",
"     : 720 mg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Mycophenolate delayed release 720 mg twice daily was shown to be bioequivalent to mycophenolate mofetil 1000 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mycophenolate mofetil: I.V., Oral:",
"     <b>",
"      Note:",
"     </b>",
"     If using I.V. route, administer within 24 hours following transplantation; can be given for up to 14 days; patients should be switched to oral formulation as soon as oral medication is tolerated:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Renal transplant: 1 g twice daily in combination with corticosteroids and cyclosporine; dosages as high as 3-3.5 g/day were used in clinical trials, but no efficacy advantage was established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cardiac transplant: 1.5 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Hepatic transplant: 1.5 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mycophenolate delayed-release tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Renal transplant: 720 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cardiac transplant: 1080 mg twice daily has been shown to be therapeutically similar to mycophenolate mofetil 1.5 g twice daily in a study of 154",
"     <i>",
"      de novo",
"     </i>",
"     heart transplant recipients and has a comparable safety profile (Kobashigawa, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment",
"     </b>",
"     : Adults: Renal transplant: GFR &lt;25 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     outside the immediate post-transplant period:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate mofetil: Avoid doses &gt;1 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate delayed release tablet: Monitor carefully",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for toxicity (neutropenia)",
"     </b>",
"     : ANC &lt;1.3 x 10",
"     <sup>",
"      3",
"     </sup>",
"     /&mu;L; dosing should be interrupted or the dose reduced",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as mofetil: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as mofetil hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: 500 mg [contains polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as mofetil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: 200 mg/mL (175 mL) [contains phenylalanine 0.56 mg/mL, soybean lecithin; mixed fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as mofetil: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CellCept&reg;: 500 mg [contains ethanol (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as mycophenolic acid: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, oral, as mycophenolic acid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myfortic&reg;: 180 mg, 360 mg [formulated as a sodium salt]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F198644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule, tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Myfortic&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM172735.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM172735.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CellCept&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM170919.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM170919.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer on an empty stomach one hour before or two hours after food; one center has mixed the contents of the capsule in chocolate syrup; mycophenolate suspension can be administered orally or via a nasogastric tube with a minimum size of 8 French; shake suspension well before use. Swallow delayed-release tablet whole; do not crush, chew, or cut.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"     <b>",
"      Do not administer I.V. push",
"     </b>",
"     or by rapid I.V. bolus injection; reconstitute vial with D",
"     <sub>",
"      5",
"     </sub>",
"     W and further dilute to a final concentration of 6 mg/mL using D",
"     <sub>",
"      5",
"     </sub>",
"     W. Administer by slow I.V. infusion over a period of no less than 2 hours.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F198717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Anidulafungin, caspofungin, cefepime, dopamine, norepinephrine, tacrolimus, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Micafungin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cyclosporine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store capsules, tablets, delayed release tablets, dry powder for oral suspension, and intact I.V. vials at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Store reconstituted suspension in refrigerator or at room temperature; stable for 60 days after reconstitution. Do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Mycophenolate I.V. infusion solution is stable for 12 hours at room temperature after preparation; administration of the infusion solution should begin within 4 hours from reconstitution and dilution of the drug. Do not mix mycophenolate with any other drugs.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunosuppressant agent used in conjunction with other immunosuppressive therapies (eg, cyclosporine and corticosteroids with or without antithymocyte induction) for the prophylaxis of organ rejection in patients receiving allogeneic renal (FDA approved in ages &ge;3 months and adults), hepatic, or cardiac transplants (FDA approved in adults); add-on immunosuppressant agent that is typically used in place of azathioprine in combination regimens for the treatment of refractory acute kidney graft rejection. Has also been used  in nephrotic syndrome; intestine, small bowel, and bone marrow transplant patients; moderate to severe psoriasis; chronic graft-versus-host disease; myasthenia gravis; lupus nephritis; autoimmune lymphoproliferative syndrome  juvenile localized scleroderma, uveitis and refractory immune thrombocytopenic purpura.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F198716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In general, lower doses used in renal rejection patients had less adverse effects than higher doses. Rates of adverse effects were similar for each indication, except for those unique to the specific organ involved. The type of adverse effects observed in pediatric patients was similar to those seen in adults, with the exception of abdominal pain, anemia, diarrhea, fever, hypertension, infection, pharyngitis, respiratory tract infection, sepsis, and vomiting; lymphoproliferative disorder was the only type of malignancy observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      As reported in adults following oral dosing of CellCept&reg; alone in renal, cardiac, and hepatic allograft rejection studies:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, hyper-/hypotension, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness,  fever, headache, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia, hyperglycemia, hypocalcemia, hyper-/hypokalemia, hypomagnesemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, nausea,  vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia (including hypochromic), leukocytosis, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Ascites, liver function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, kidney function abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, lung disorder, pleural effusion, respiratory tract infection, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous:",
"     <i>",
"      Candida",
"     </i>",
"     , herpes simplex, lactate dehydrogenase increased, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Use in combination with cyclosporine and corticosteroids:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, arrhythmia, arterial thrombosis, atrial fibrillation, atrial flutter, bradycardia, cardiac arrest, cardiac failure, CHF, extrasystole, facial edema, hyper-/hypovolemia, orthostatic hypotension, pallor, palpitation, pericardial effusion, peripheral vascular disorder, supraventricular extrasystoles, supraventricular tachycardia, syncope, thrombosis, vasodilation, vasospasm, venous pressure increased, ventricular extrasystole, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, chills with fever, confusion, delirium, depression, emotional lability, hallucinations, hypoesthesia, malaise, nervousness, psychosis, seizure, somnolence, thinking abnormal, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, bruising, cellulitis, fungal dermatitis, hirsutism, petechia, pruritus, skin carcinoma, skin hypertrophy, skin ulcer, vesiculobullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, alkalosis, Cushing's syndrome, dehydration, diabetes mellitus, gout, hypercalcemia, hyper-hypophosphatemia, hyperlipemia, hyperuricemia, hypochloremia, hypoglycemia, hyponatremia, hypoproteinemia, hypothyroidism, parathyroid disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged, dysphagia, esophagitis, flatulence, gastritis, gastroenteritis, gastrointestinal hemorrhage, gastrointestinal moniliasis, gingivitis, gum hyperplasia, ileus, melena, mouth ulceration, oral moniliasis, stomach disorder, stomach ulcer, stomatitis, xerostomia, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, nocturia, pelvic pain, prostatic disorder, scrotal edema, urinary frequency, urinary incontinence, urinary retention, urinary tract disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Coagulation disorder, hemorrhage, neutropenia, pancytopenia, polycythemia, prothrombin time increased, thromboplastin time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, bilirubinemia, cholangitis, cholestatic jaundice, GGT increased, hepatitis, jaundice, liver damage, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Abscess",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, hypertonia, joint disorder, leg cramps, myalgia, myasthenia, neck pain, neuropathy, osteoporosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia, cataract, conjunctivitis, eye hemorrhage, lacrimation disorder, vision abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Deafness, ear disorder, ear pain, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria, creatinine increased, dysuria, hematuria, hydronephrosis, oliguria, pyelonephritis, renal failure, renal tubular necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, asthma, atelectasis, bronchitis, epistaxis, hemoptysis, hiccup, hyperventilation, hypoxia, respiratory acidosis, pharyngitis, pneumonia, pneumothorax, pulmonary edema, pulmonary hypertension, respiratory moniliasis, rhinitis, sputum increased, voice alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous:",
"     <i>",
"      Candida",
"     </i>",
"     (mucocutaneous), CMV tissue invasive disease, CMV viremia/syndrome, herpes zoster cutaneous disease, cyst, diaphoresis, flu-like syndrome, healing abnormal, hernia, ileus infection, neoplasm, peritonitis, thirst",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Atypical mycobacterial infection, BK virus-associated nephropathy, colitis, gastrointestinal perforation, infectious endocarditis, interstitial lung disorder, intestinal villous atrophy, lymphoma, lymphoproliferative disease, malignancy, meningitis, pancreatitis, progressive multifocal leukoencephalopathy (sometimes fatal), pulmonary fibrosis (fatal), pure red cell aplasia, tuberculosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mycophenolate mofetil, mycophenolate sodium, mycophenolic acid, polysorbate 80 (I.V. formulation), or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with active serious digestive disease and in patients with renal impairment; modify dosage in patients with severe chronic renal impairment (GFR &lt;25 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     outside of the immediate post-transplant period) and in patients with neutropenia. Avoid use in patients with rare hereditary deficiency of hypoxanthineguanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome. The oral suspension contains aspartame which is metabolized to phenylalanine and must be used with caution in patients with phenylketonuria. Administer under the supervision of a physician experienced in immunosuppressive therapy and management of transplant patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Immunosuppression with mycophenolate may result in an increased susceptibility to infection and an increased risk of developing lymphomas and other malignancies, particularly of the skin",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk appears to be associated with the intensity and duration of immunosuppression; patients should be instructed to limit exposure to sunlight and ultraviolet light. Lymphoproliferative disorder has been reported in pediatric patients. Mycophenolate is associated with an increased risk of first trimester pregnancy loss, teratogenic effects, and congenital malformations, including external ear, facial abnormalities, cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, and kidney",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; women using mycophenolate during pregnancy should be encouraged to enroll in the National Transplantation Pregnancy Registry. In women of childbearing potential, two reliable forms of contraception must be initiated 4 weeks before starting mycophenolate therapy, maintained during therapy, and continued for 6 weeks after it has been discontinued. Neutropenia (including severe neutropenia) may occur, requiring dose reduction or interruption of treatment (risk greater from day 31-180 post-transplant ). Pure red cell aplasia (PRCA), a type of anemia which can range from subclinical to severe has been reported in patients receiving mycophenolate concomitantly with other immunosuppressive agents (eg, tacrolimus, cyclosporine, corticosteroids). Symptoms may include fatigue, lethargy, or pallor. Although not precisely known, risk factors for the development of PRCA may include immunosuppression and treatment with immunosuppressant therapy. Dose reduction or discontinuation of immunosuppressive therapy may reverse PRCA; however, in transplant recipients, the risk of reduced immunosuppression and graft rejection should be considered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Cases of progressive multifocal leukoencephalopathy (PML) have been associated with mycophenolate use; consider PML in the differential diagnosis in patients reporting neurological symptoms. Pure red cell aplasia has been reported with use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     CellCept&reg; and Myfortic&reg; dosage forms should not be used interchangeably due to differences in absorption.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: Mycophenolate may increase the serum concentration of Acyclovir-Valacyclovir. Acyclovir-Valacyclovir may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Mycophenolate. Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belatacept: May increase serum concentrations of the active metabolite(s) of Mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the serum concentration of Mycophenolate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Mycophenolate may decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination.  Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Mycophenolate may decrease the serum concentration of Contraceptives (Progestins).  Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the serum concentration of Mycophenolate. Specifically, cyclosporine may decrease concentrations of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Mycophenolate may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Mycophenolate. Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May decrease the serum concentration of Mycophenolate. Specifically, metronidazole may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Mycophenolate. Specifically, rifamycin derivatives may decrease the concentration of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sevelamer: May decrease the serum concentration of Mycophenolate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1048795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Presence of food decreases mycophenolate peak concentration by 40% following mycophenolate mofetil and 33% following mycophenolate delayed release oral tablet, but has no effect on the extent of absorption; avoid echinacea (has immunostimulant property)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F198655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F198668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Mycophenolate is associated with an increased risk of congenital malformations and first trimester pregnancy loss when used by pregnant women. Females of reproductive potential must be counseled about pregnancy prevention and planning.",
"     </b>",
"     Alternative agents should be considered for women planning a pregnancy. Adverse events have been reported in animal studies at doses less than the equivalent recommended human dose. In humans, the following congenital malformations have been reported: external ear abnormalities, cleft lip and palate, anomalies of the distal limbs, heart, esophagus and kidney. Spontaneous abortions have also been noted. Females of reproductive potential (girls who have entered puberty, women with a uterus who have not passed through clinically confirmed menopause) should have a negative pregnancy test with a sensitivity of &ge;25 mIU/mL immediately before therapy and the test should be repeated 8-10 days later.  Pregnancy tests should be repeated during routine follow-up visits. Acceptable forms of contraception should be used during treatment and for 6 weeks after therapy is discontinued. The effectiveness of hormonal contraceptive agents may be affected by mycophenolate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers should report female exposures to mycophenolate during pregnancy or within 6 weeks of discontinuing therapy to the Mycophenolate Pregnancy Registry (800-617-8191). The National Transplantation Pregnancy Registry (NTPR, Temple University) is a registry for pregnant women taking immunosuppressants following any solid organ transplant. The NTPR encourages reporting of all immunosuppressant exposures during pregnancy in transplant recipients at 877-955-6877.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, serum electrolytes, glucose, phosphate, cholesterol, and renal function tests; blood pressure. Pregnancy test in female patients of childbearing potential within 1 week prior to beginning therapy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydrolyzed to form mycophenolic acid (MPA), the active metabolite, which is a potent, uncompetitive reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) in the purine biosynthesis pathway; inhibition of IMPDH results in a depletion of guanosine triphosphate and deoxyguanosine triphosphate, thereby inhibiting T- and B-cell proliferation, cytotoxic T-cell generation and antibody secretion.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and extensive; early post-transplant period MPA AUC values are approximately 45% to 53% lower than later post-transplant period (&gt;3 months) MPA AUC values in pediatric patients 1-18 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Mean V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate mofetil: MPA: Oral: 4 L/kg; I.V. 3.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate delayed release tablet: MPA: Oral: 54 L (at steady state)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate glucuronide: 82%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Mycophenolate mofetil and enteric-coated mycophenolate sodium undergo hydrolysis by esterases to mycophenolic acid (MPA is the active metabolite); MPA is metabolized by glucuronyl transferase to mycophenolic acid glucuronide (MPAG is inactive). MPAG is converted to MPA via enterohepatic recirculation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate mofetil: 80.7% to 94%; enterohepatic recirculation contributes to MPA concentration; two 500 mg tablets have been shown to be bioequivalent to four 250 mg capsules or 1000 mg of oral suspension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enteric-coated mycophenolate sodium: 72%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate mofetil: MPA: Oral: 18 hours; I.V.: 17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate delayed release: MPA: Oral: 8-16 hours; MPAG: 13-17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate mofetil: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate sodium: 1.5-2.75 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate mofetil: 6% in feces; 87% of mycophenolic acid dose recovered as MPAG in urine; &lt;1% of dose excreted as MPA in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycophenolate delayed release: 3% excreted as MPA in urine and in feces; &gt;60% recovered as MPAG in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/56/22406?source=see_link\">",
"      see \"Mycophenolate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take within 1 hour before or 2 hours after antacids or cholestyramine; maintain adequate hydration. You will be susceptible to infection (avoid crowds and people with infections). Report to physician any diarrhea, vomiting, stomach pain, leg swelling, chest pain, acute headache or dizziness, respiratory infection symptoms, difficulty breathing, fatigue, lethargy, abnormal skin paleness, or unusual bleeding or bruising. You may be at increased risk for skin cancer (wear protective clothing and use sunscreen). Women of childbearing age should use two effective forms of contraception simultaneously for 4 weeks before starting mycophenolate therapy, during therapy, and for 6 weeks after discontinuing mycophenolate, unless abstinence is the chosen method of contraception.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10073346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A direct conversion factor from mycophenolate mofetil to mycophenolic acid (delayed release) is not available. In one study, adults on mycophenolate mofetil 1000 mg twice daily were successfully converted to mycophenolic acid (delayed release) 720 mg twice daily. In the same study, children (n= 17) were converted from 440 &plusmn; 147 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily to mycophenolic acid (delayed release) 432 &plusmn; 51 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily (Massari, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10893685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 50 mg/mL oral suspension may be made with mycophenolate mofetil capsules, Ora-Plus&reg;, and cherry syrup. In a vertical flow hood, empty six 250 mg capsules into a mortar; add 7.5 mL Ora-Plus&reg; and mix to a uniform paste. Mix while adding 15 mL of cherry syrup in incremental proportions; transfer to a calibrated bottle, rinse mortar with cherry syrup, and add sufficient quantity of cherry syrup to make 30 mL. Label \"shake well\". Stable for 210 days at 5&deg;C, for 28 days at 25&deg;C to 37&deg;C, and for 11 days at 45&deg;C.",
"    </p>",
"    <div class=\"reference\">",
"     Venkataramanan R, McCombs JR, Zuckerman S, et al, \"Stability of Mycophenolate Mofetil as an Extemporaneous Suspension,\"",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 1998, 32(7-8):755-7.",
"     <span class=\"pubmed-id\">",
"      9681090",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12072/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12072/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ettenger R, Warshaw B, Menster M, et al, &ldquo;Mycophenolate Mofetil in Pediatric Renal Transplantation: A Report of the Ped MMF Study Group.&rdquo; Abstract: 1996, Annual Meeting, ASTP.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gipson DS, Massengill SF, Yao L, et al, \"Management of Childhood Onset Nephrotic Syndrome,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(2):747-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12072/abstract-text/19651590/pubmed\" id=\"19651590\" target=\"_blank\">",
"        19651590",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogg RJ, Fitzgibbons L, Bruick J, et al, \"Mycophenolate Mofetil in Children With Frequently Relapsing Nephrotic Syndrome: A Report From the Southwest Pediatric Nephrology Study Group,\"",
"      <i>",
"       Clin J Am Soc Nephrol",
"      </i>",
"      , 2006, 1(6):1173-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12072/abstract-text/17699344/pubmed\" id=\"17699344\" target=\"_blank\">",
"        17699344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kobashigawa JA, Renlund DG, Gerosa G, et al, \"Similar Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS, Myfortic) Compared With Mycophenolate Mofetil (MMF) in",
"      <i>",
"       de novo",
"      </i>",
"      Heart Transplant Recipients: Results of a 12-Month, Single-Blind, Randomized, Parallel-Group, Multicenter Study,\"",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2006, 25(8):935-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12072/abstract-text/16890114 /pubmed\" id=\"16890114 \" target=\"_blank\">",
"        16890114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Massari P, Duro-Garcia V, Gir&oacute;n F, et al, \"Safety Assessment of the Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Renal Transplant Recipients,\"",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 2005, 37(2):916-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12072/abstract-text/15848574/pubmed\" id=\"15848574\" target=\"_blank\">",
"        15848574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sollinger HW, &ldquo;Mycophenolate Mofetil for the Prevention of Acute Rejection in Primary Cadaveric Renal Allograft Recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1995, 60:225-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12072/abstract-text/7645033/pubmed\" id=\"7645033\" target=\"_blank\">",
"        7645033",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Staatz CE and Tett SE, \"Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2007, 46(1):13-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/50/12072/abstract-text/17201457/pubmed\" id=\"17201457\" target=\"_blank\">",
"        17201457",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12624 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12072=[""].join("\n");
var outline_f11_50_12072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709159\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198686\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198687\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048786\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048778\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198659\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198644\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874743\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048789\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198717\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048781\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048788\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198716\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048793\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048777\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048776\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299731\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198653\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048795\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198655\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198668\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048785\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048775\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048792\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048783\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10073346\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10893685\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12624\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12624|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=related_link\">",
"      Mycophenolate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/56/22406?source=related_link\">",
"      Mycophenolate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_50_12073="Remission criteria in acute myeloid leukemia and monitoring for residual disease";
var content_f11_50_12073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/50/12073/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/50/12073/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/50/12073/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/50/12073/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/50/12073/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/50/12073/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/50/12073/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction therapy in the acute leukemias aims to reduce the total body leukemic cell population from approximately 10",
"    <sup>",
"     12",
"    </sup>",
"    to below the cytologically detectable level of about 10",
"    <sup>",
"     9",
"    </sup>",
"    cells. It is generally assumed, however, that a substantial burden of leukemia cells persists undetected (ie, \"minimal residual disease\"), leading to relapse within a few weeks or months if no further post-remission therapy (ie, additional consolidation chemotherapy) were administered. However, even when an adult patient is in complete remission (CR) following additional induction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consolidation therapy, the majority will ultimately relapse, indicating that attainment of CR, as defined below, is not sufficient to guarantee long-term remission",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    \"cure\". (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review will discuss the subject of minimal residual disease in patients who have been treated for acute myeloid leukemia (AML) and are in complete remission. Standard morphologic and cytologic methods for diagnosing de novo or relapsed leukemia are discussed separately, although their limitations are briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF COMPLETE REMISSION (CR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete remission in AML has been defined using the following criteria developed by an International Working Group (",
"    <a class=\"graphic graphic_table graphicRef60024 \" href=\"UTD.htm?1/5/1118\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal values for absolute neutrophil count",
"      <span class=\"nowrap\">",
"       (&gt;1000/microL)",
"      </span>",
"      and platelet count",
"      <span class=\"nowrap\">",
"       (&gt;100,000/microL),",
"      </span>",
"      and independence from red cell transfusion.",
"     </li>",
"     <li>",
"      A bone marrow biopsy that reveals no clusters or collections of blast cells. Extramedullary leukemia (eg, central nervous system or soft tissue involvement) must be absent.",
"     </li>",
"     <li>",
"      A bone marrow aspiration reveals normal maturation of all cellular components (ie, erythrocytic, granulocytic, and megakaryocytic series). There is no requirement for bone marrow cellularity.",
"     </li>",
"     <li>",
"      Less than 5 percent blast cells are present in the bone marrow, and none can have a leukemic phenotype (eg, Auer rods). The persistence of dysplasia is worrisome as an indicator of residual AML but has not been validated as a criterion for remission status.",
"     </li>",
"     <li>",
"      The absence of a previously detected clonal cytogenetic abnormality (ie, complete cytogenetic remission, CRc) confirms the morphologic diagnosis of CR but is not currently a required criterion. However, conversion from an abnormal to a normal karyotype at the time of first CR is an important prognostic indicator, supporting the use of CRc as a criterion for CR in AML [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/2,4,5\">",
"       2,4,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Other responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients may fulfill all of the above criteria for CR but may not recover peripheral blood counts to the required level. These are denoted as CRi, or CR with insufficient hematological recovery (platelets or neutrophils). CRp describes a subset of patients with CRi, wherein patients fulfill all criteria for CR except that platelet counts are",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. The survival and relapse rates for patients with CRp appear to be worse than those with a CR, but better than those with a partial remission (PR) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who fail to achieve CR or CRi may experience a PR, defined as a &ge;50 percent decrease in bone marrow blasts with normalization of peripheral blood counts, or some other measure of hematologic improvement. A PR in AML is generally expected to be of short duration, and, in most circumstances, is unlikely to serve as a surrogate reasonably likely to predict for clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As will be seen below, techniques employing the polymerase chain reaction (PCR) and multiparametric flow cytometry are significantly more sensitive for detecting the presence or absence of residual disease (ie, complete molecular remission, CRm). However, with the exception of acute promyelocytic leukemia, the clinical utility of this assay is uncertain, since not all patients with PCR evidence for residual disease will relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\", section on 'Molecular genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CR AS DEFINED BY LONG-TERM SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear guideline for how often bone marrow biopsies should be performed in patients who obtain a complete clinical remission (CR) after therapy. Many patients treated on protocol have a bone marrow aspiration repeated every two to three months during the first year after attainment of CR and every three to six months for the next two years. In fact, most relapses are signaled by a decline in the platelet count to abnormal levels or the appearance of leukemic blasts in the peripheral blood smear. In general, for non-protocol patients, a single bone marrow exam performed two to three months after the completion of treatment is likely sufficient as long as the complete blood count remains normal.",
"   </p>",
"   <p>",
"    The risk of relapse is highest during the first two years after the end of consolidation chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. It is relatively uncommon to have a late relapse.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using data from nine trials initiated by the Cancer and Leukemia Group B (CALGB) between 1974 and 1992, hazard rates for death and relapse were found to be greatest in the first year, decreased substantially between years 1 and 2, and decreased further between years 2 and 3 [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/9\">",
"       9",
"      </a>",
"      ]. Rates of death and relapse were quite low after 3 to 4 years. It was concluded that patients with AML who are in complete remission for 3 to 4 years can be reassured that late relapse and death are relatively uncommon events.",
"     </li>",
"     <li>",
"      A single-institution retrospective study looked at the long-term outcomes in 1069 consecutive patients with AML in first complete remission from 1991 to 2003 [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/10\">",
"       10",
"      </a>",
"      ]. Relapse rates decreased as the patients were further from treatment with rates of 69, 38, 17, 8, and 7 percent during years one through five, respectively.",
"     </li>",
"     <li>",
"      Among patients with AML who received hematopoietic cell transplantation and were in CR two years later, the overall chance of being alive in CR at nine years was 82 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/11\">",
"       11",
"      </a>",
"      ]. The latest relapses in this group occurred at four to seven years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFICULTIES IN DEFINING CR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observations illustrate the problems involved in ascertaining whether a patient in complete remission (CR) is destined to remain clinically disease-free:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sampling error",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sampling error of a single bone marrow examination is immense, as the examined specimen represents only a very small percentage of the total bone marrow cellular population. Many documented cases exist in which a bone marrow aspiration was normal at one site and showed leukemia at another [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sensitivity of routine tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard definitions of CR in acute leukemia require that blasts constitute less than 5 percent of the total nonerythroid cells within the bone marrow. Therefore, up to 5000",
"    <span class=\"nowrap\">",
"     blasts/100,000",
"    </span>",
"    nonerythroid cells may still be present in a patient in clinical CR. Other testing limitations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sensitivity of cytogenetics for detecting residual disease is limited to about 5 percent when only 20 to 40 metaphase cells are examined.",
"     </li>",
"     <li>",
"      In one study, the median lower limit of detection of leukemic blasts by conventional microscopic examination of bone marrow by two experienced cytologists was greater than 1 percent. That is, even experienced observers have difficulty detecting fewer than 1000 leukemic",
"      <span class=\"nowrap\">",
"       blasts/100,000",
"      </span>",
"      nucleated cells [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is common experience that seeing a single myeloblast with an Auer rod in a remission bone marrow examination is a harbinger of persistent AML. Since most bone marrow examinations review fewer than 1000 nucleated cells, even a single observable blast cell represents approximately 100",
"      <span class=\"nowrap\">",
"       blasts/100,000",
"      </span>",
"      nucleated cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF PCR AND FLOW CYTOMETRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods of monitoring for minimal residual disease in AML include real time quantitative polymerase chain reaction (RQ-PCR) and multiparameter flow cytometry (MFC). Each method has associated benefits and complications [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. With each of these methods the presence of cells from the leukemic clone is not, in itself, an indication that relapse is imminent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Such cells might be incapable of division or proliferation, might be able to divide but not mature, or might be held in check by the patient's immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous technical and practical areas of uncertainty remain regarding MRD monitoring in AML:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type of sample &mdash; Peripheral blood is easy to obtain and lacks immature normal populations of cells that may interfere with analysis by MFC. However, the sensitivity of MRD analysis of the peripheral blood is lower than that of bone marrow and requires a lower MRD threshold to be prognostic.",
"     </li>",
"     <li>",
"      Sample size &nbsp;",
"     </li>",
"     <li>",
"      Timing (eg, during induction, after induction, after consolidation)",
"     </li>",
"     <li>",
"      Sampling interval (eg, every three months)",
"     </li>",
"     <li>",
"      Length of screening",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of importance, variables that affect the ability of MRD monitoring to have an impact on patient outcome differ by AML genetic subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/21\">",
"     21",
"    </a>",
"    ]. The ideal timing as well as sampling interval for MRD monitoring and the length of screening for relapse is unknown and likely differs depending upon the molecular marker used. As an example, AML clones with certain molecular lesions are known to replicate at faster or slower rates than others, resulting in a wide range of elapsed time between the emergence of a positive MRD sample and hematologic relapse. To be effective, a genetic subtype with a short time period between the emergence of MRD and hematologic relapse may require more frequent MRD monitoring than a subtype with a slower progression. Similarly, a genetic subtype that progresses more slowly may require more prolonged MRD monitoring. In addition, the rate of fusion transcript degradation varies by molecular marker.",
"   </p>",
"   <p>",
"    While MRD assessment appears to have prognostic value, it is unknown whether MRD assessment will have therapeutic consequences that will improve long-term outcomes. These and other logistical aspects to MRD monitoring must be clarified and validated in rigorous clinical trials before MRD monitoring can become part of the routine follow-up of all patients with AML.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Real time quantitative polymerase chain reaction (RQ-PCR) can be used to look for fusion gene transcripts (eg, BCR-ABL), gene mutations (eg,",
"    <span class=\"nowrap\">",
"     FLT3-LM/ITD),",
"    </span>",
"    or aberrantly expressed genes (eg, WT1). The leukemic cells must express (or overexpress) a gene not seen in normal cells. RQ-PCR is then used to compare mRNA expression of these targeted genes to that of reference housekeeping genes. RQ-PCR is a potential technique for measuring residual disease in more than half of patients with AML.",
"   </p>",
"   <p>",
"    Currently available PCR techniques are able to detect approximately one leukemia cell diluted 10",
"    <sup>",
"     5",
"    </sup>",
"    to 10",
"    <sup>",
"     6",
"    </sup>",
"    times, or one blast or less per 100,000 nucleated cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/6,13,22,23\">",
"     6,13,22,23",
"    </a>",
"    ]. As an example, one study that used PCR to estimate the numbers of residual leukemic cells found that the relapse rates for children with &lt;15 or &gt;15",
"    <span class=\"nowrap\">",
"     blasts/100,000",
"    </span>",
"    mononuclear cells after the end of induction and consolidation therapy were 4 and 47 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/13\">",
"     13",
"    </a>",
"    ]. Details on the procedure of PCR are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=see_link\">",
"     \"General aspects of cytogenetic analysis in hematologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The above calculations indicate that routine microscopic determination of clinical complete remission status (&lt;5000",
"    <span class=\"nowrap\">",
"     blasts/100,000",
"    </span>",
"    cells) allows for a residual blast count up to 300 times greater than the number associated with leukemic relapse (&gt;15",
"    <span class=\"nowrap\">",
"     blasts/100,000",
"    </span>",
"    cells). Even the chance observation of a single blast cell containing an Auer rod (see above) indicates a residual blast count approximately seven times that associated with ultimate relapse. These observations would lead one to conclude that \"true\" complete remissions must be determined by techniques at least as sensitive as PCR (",
"    <a class=\"graphic graphic_table graphicRef70804 \" href=\"UTD.htm?24/37/25179\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are some known limitations to the use of PCR for the detection of minimal residual disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/14,24\">",
"     14,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no standardized method for RQ-PCR measurement of minimal residual disease across laboratories such that values cannot be compared between different laboratories.",
"     </li>",
"     <li>",
"      PCR techniques require that the genome of the leukemic clone is sufficiently different from the normal clone in order to prepare the appropriate primers and probes. This may be relatively straightforward for common recurring translocations in AML, such as t(15;17), and inv(16) or, in ALL, clonal rearrangements of the T-cell receptor or immunoglobulin genes [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/13,22,23,25,26\">",
"       13,22,23,25,26",
"      </a>",
"      ], but would not be possible in the absence of detectable genetic alterations unless the leukemic cells express (or overexpress) a gene not seen in normal cells [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As a result of chemotherapy or clonal evolution, a genetic subclone might develop with a genetic makeup different from the primary leukemic clone [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/29\">",
"       29",
"      </a>",
"      ]. This clone might expand, leading to a leukemic \"relapse\" but would not be detected with the same PCR primer pairs and probes used for the original clone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These markers require rigorous clinical validation before they are used clinically. This validation would help assure that marker positivity would truly reflect an increased risk of relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Multiparameter flow cytometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiparametric flow cytometry (MPC) can be used at diagnosis to identify leukemia-associated aberrant immunophenotypes (LAIPs) which are present on malignant cells in the bone marrow but not found on the patient's normal cells. MPC can be performed in about 80 percent of cases of AML, with a sensitivity of about one blast cell in 10",
"    <sup>",
"     3",
"    </sup>",
"    to 10",
"    <sup>",
"     4",
"    </sup>",
"    nucleated cells, depending on the antigenic marker [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are some limitations to the use of MPC for detecting minimal residual disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple LAIPs have been identified in patients with AML, but each individual LAIP may only be present in &lt;5 percent of patients thereby requiring an extensive panel at diagnosis in order to identify an appropriate LAIP for the patient.",
"     </li>",
"     <li>",
"      Malignant cells within an individual patient may display phenotypic heterogeneity such that some leukemic cells may not express the LAIP and therefore go undetected by this method.",
"     </li>",
"     <li>",
"      In a minority of cases, the LAIP expressed by the malignant cells may change from diagnosis to relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SIGNIFICANCE OF RESIDUAL DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Detected by PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of patients with continuous morphologic complete remission but who still have tumor cells, as determined by reverse transcriptase PCR (RT-PCR), is not known. Serial quantitative measurements may be helpful; finding increasing values for minimal residual disease at various time points in the course of the disease may identify patients at higher risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/13,22,23,30-35\">",
"     13,22,23,30-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Use in APL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic importance of MRD has been noted in studies that performed serial RT-PCR studies in patients undergoing treatment for newly-diagnosed acute promyelocytic leukemia (APL) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest study followed serial real time quantitative PCR (RQ-PCR) assays every three months from peripheral blood and bone marrow samples of 406 patients with newly diagnosed APL undergoing induction therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/36\">",
"       36",
"      </a>",
"      ]. APL persisted or recurred at the molecular or clinical level in 30 patients. Of the 20 patients with frank relapse, 11 demonstrated RQ-PCR positivity in samples collected a median of 74 days before. Of the nine patients with frank relapse not detected by RQ-PCR, seven had been non-compliant with their RQ-PCR monitoring schedule.",
"     </li>",
"     <li>",
"      In another study, 40 of 47 patients (85 percent) who were induced by ATRA alone had residual disease detected by RT-PCR [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/37\">",
"       37",
"      </a>",
"      ]. However, after three cycles of consolidation therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"       idarubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , residual disease was found in only 10 percent. APL relapsed in only 3 of 41 patients (7 percent) who had two or more negative RT-PCR assays for MRD compared with all four patients with two or more positive results.",
"     </li>",
"     <li>",
"      A third study of 123 patients found that patients having a ratio of PML-RARalpha mRNA to that of the housekeeping enzyme GAPDH greater than 10",
"      <sup>",
"       -5",
"      </sup>",
"      following consolidation therapy were at a fourfold increased risk for relapse compared with those with a ratio of less than 10",
"      <sup>",
"       -5",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/38\">",
"       38",
"      </a>",
"      ]. However, 73 percent of patients who experienced relapse had ratios less than 10",
"      <sup>",
"       -5",
"      </sup>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Monitoring of minimal residual disease is routinely incorporated into the post-consolidation care of patients with APL. Such monitoring is only useful if done frequently with a planned intervention as soon as a positive signal is seen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Monitoring response during maintenance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Use in non-APL AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of minimal residual disease monitoring in patients with non-APL AML is less clear. Decisions on whether to continue therapy cannot at present be based solely upon a positive signal with RT-PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/41\">",
"     41",
"    </a>",
"    ]. The following examples illustrate this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients with t(8;21) who have been treated for AML have had positive evidence for the",
"      <span class=\"nowrap\">",
"       AML1/ETO",
"      </span>",
"      <span class=\"nowrap\">",
"       (AML1/MTG8)",
"      </span>",
"      fusion gene by RT-PCR for as long as eight years without relapsing [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/18,42\">",
"       18,42",
"      </a>",
"      ]. On the other hand, patients who become RT-PCR negative have a low rate of relapse and are probably cured [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/17,43\">",
"       17,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In six patients with AML and t(6;11) who achieved clinical CR, the MLL-AF6 fusion transcript was detected by RT-PCR in five after completion of treatment. The one patient achieving molecular CR was alive and in continuous CR at 33 months, while all five MLL-AF6 positive patients relapsed, with a median event-free survival of 7 months [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An international study evaluated RT-PCR for the Wilms tumor gene (WT1) in AML patient samples obtained at diagnosis (620 patients), post-induction chemotherapy (129 patients), or in healthy controls (204 persons) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/45\">",
"       45",
"      </a>",
"      ]. A greater reduction in WT1 transcript level after induction chemotherapy was predictive of a lower risk of AML relapse.",
"     </li>",
"     <li>",
"      In a study of 424 patients with AML undergoing transplantation, 93 patients (22 percent) had informative discordant results from concurrent cytogenetics and flow cytometry testing (ie, negative cytogenetics with positive flow or positive cytogenetics with negative flow) either before or after transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/46\">",
"       46",
"      </a>",
"      ]. Detection of residual disease by either method at either time was associated with a higher relapse rate and worse survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sequential signal changes that can occur with treatment were illustrated in a report of 25 patients with AML and t(8;21) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/42\">",
"     42",
"    </a>",
"    ]. In general, induction chemotherapy produced a two to three log reduction in the level of",
"    <span class=\"nowrap\">",
"     AML1/ETO",
"    </span>",
"    mRNA in both bone marrow and peripheral blood;",
"    <span class=\"nowrap\">",
"     consolidation/intensification",
"    </span>",
"    chemotherapy produced a further two to three log reduction. The remaining level was predictive of the subsequent outcome. Levels of &le;10",
"    <sup>",
"     3",
"    </sup>",
"    <span class=\"nowrap\">",
"     molecules/microg",
"    </span>",
"    of RNA in bone marrow and &le;10",
"    <sup>",
"     2",
"    </sup>",
"    <span class=\"nowrap\">",
"     molecules/microg",
"    </span>",
"    in peripheral blood were compatible with prolonged remission. Patients with substantially higher levels relapsed. Similar results have been reported for patients with AML and inv(16) (",
"    <a class=\"graphic graphic_figure graphicRef50902 \" href=\"UTD.htm?1/0/1038\">",
"     figure 1",
"    </a>",
"    ), CBFB-MYH11,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    NPM-1 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/26,47-50\">",
"     26,47-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Detected by flow cytometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, it is also possible to monitor minimal residual disease (MRD) in children and adults with AML through flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/24,51-57\">",
"     24,51-57",
"    </a>",
"    ]. The cut-off values in these studies have been derived from retrospective analysis, and appropriate prospective validation to confirm their results is still lacking. The following studies illustrate the clinical relevance of this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, the sensitivity of this technique was similar to that noted for PCR, namely one leukemic cell diluted 10",
"      <sup>",
"       4",
"      </sup>",
"      to 10",
"      <sup>",
"       5",
"      </sup>",
"      times [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/54\">",
"       54",
"      </a>",
"      ]. Using this methodology in 34 patients with AML, a level of MRD greater than or less than 3.5 x 10",
"      <sup>",
"       -4",
"      </sup>",
"      following consolidation therapy was associated with relapse rates of 77 and 17 percent, respectively (p&lt;0.001). MRD above this cut-off value was also significantly associated with a multidrug resistance 1 (MDR1) phenotype and intermediate or unfavorable cytogenetics [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A retrospective study by the same investigators used a level of MRD greater than or less than 3.5 x10",
"      <sup>",
"       -4",
"      </sup>",
"      after consolidation chemotherapy but before transplantation in combination with data on tumor karyotype to risk stratify 143 adults with de novo AML [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/58\">",
"       58",
"      </a>",
"      ]. Patients with a good or intermediate risk karyotype that had MRD less than 3.5 x10",
"      <sup>",
"       -4",
"      </sup>",
"      post-consolidation therapy had four-year relapse free survival and overall survival rates of 58 and 73 percent, respectively. In contrast, all other patients were considered to have high risk disease and had four-year relapse-free and overall survival rates of 22 and 17 percent, respectively.",
"     </li>",
"     <li>",
"      In another study, MRD was evaluated by flow cytometry in the first bone marrow of 126 patients with AML and aberrant phenotypes following attainment of complete remission (CR) after induction therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/55\">",
"       55",
"      </a>",
"      ]. The cumulative rates of relapse were 0, 14, 50, and 84 percent for those with levels of MRD less than 10",
"      <sup>",
"       -4",
"      </sup>",
"      , between 10",
"      <sup>",
"       -4",
"      </sup>",
"      and 10",
"      <sup>",
"       -3",
"      </sup>",
"      , between 10",
"      <sup>",
"       -3",
"      </sup>",
"      and 10",
"      <sup>",
"       -2",
"      </sup>",
"      , and &gt;10",
"      <sup>",
"       -2",
"      </sup>",
"      , respectively. Multivariate analysis indicated that MRD was the most powerful independent prognostic factor, followed by cytogenetics and the number of cycles needed to achieve CR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RELAPSED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;We consider patients to have relapsed disease if, after attainment of complete molecular remission, subsequent analyses confirm the loss of such molecular remission. Relapse occurs in 5 to 10 percent of patients with APL and in about 10 to 15 percent of those with high-risk APL. Attempts have been made to identify patients during remission who are at highest risk of relapse using reverse transcriptase-polymerase chain reaction (PCR) analysis of the",
"    <span class=\"nowrap\">",
"     PML/RAR-alpha",
"    </span>",
"    fusion gene derived from the t(15;17) translocation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=see_link&amp;anchor=H261038589#H261038589\">",
"     \"Treatment of relapsed or refractory acute myeloid leukemia\", section on 'Definitions of relapse and refractory disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A multicenter Italian trial prospectively monitored PCR positivity in 163 patients with APL [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/59\">",
"     59",
"    </a>",
"    ]. All patients were in hematologic remission and tested PCR-negative at the end of consolidation. Of 21 who later converted to PCR-positivity, 20 underwent relapse at a median time of three months from the first PCR-positive result. Of 142 who were persistently PCR-negative, only eight had hematologic relapse after a median follow-up of 18 months. It is not yet known if early detection will translate into improved treatment of relapsed disease.",
"   </p>",
"   <p>",
"    The mechanisms responsible for relapse are unclear, but at least two causes of acquired ATRA resistance have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insufficient plasma ATRA concentration may be caused by increased oxidative catabolism of ATRA by cytochrome P450 enzyme activity, increases in cellular retinoic acid binding protein, or the multidrug resistance (MDR) glycoprotein [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/60-63\">",
"       60-63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subset of patients with relapse and ATRA resistance, missense mutations have been found in the RAR-alpha region of the",
"      <span class=\"nowrap\">",
"       PML/RAR-alpha",
"      </span>",
"      gene, which may interfere with the molecular interaction with ATRA [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12073/abstract/63,64\">",
"       63,64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22652924\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction therapy for acute myeloid leukemia (AML) aims to achieve a complete remission (CR) in which the total body leukemic cell population is reduced from approximately 10",
"      <sup>",
"       12",
"      </sup>",
"      to below the cytologically detectable level of about 10",
"      <sup>",
"       9",
"      </sup>",
"      cells. Thus, it is generally assumed that a substantial burden of leukemia cells persists undetected (ie, \"minimal residual disease\"), leading to relapse within a few weeks or months if no further post-remission therapy (ie, additional consolidation chemotherapy) were administered.",
"     </li>",
"     <li>",
"      CR is defined by International Working Group criteria using morphologic and clinical data (",
"      <a class=\"graphic graphic_table graphicRef60024 \" href=\"UTD.htm?1/5/1118\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of complete remission (CR)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ascertaining whether a patient in CR is destined to remain clinically disease-free after post-remission therapy is limited by the inherent insensitivity of routine tests on the bone marrow for detecting residual leukemia and the likelihood that the small area of bone marrow examined does not reflect the much larger bone marrow compartment. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Difficulties in defining CR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Techniques employing real time quantitative polymerase chain reaction (RQ-PCR) and multiparameter flow cytometry techniques are significantly more sensitive for detecting the presence or absence of minimal residual disease (MRD) than morphology or cytogenetics. Each method has associated benefits and complications. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Limitations of PCR and flow cytometry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PCR analysis is routinely used to confirm a complete remission in patients with acute promyelocytic leukemia (APL). Prospective monitoring of MRD by RT-PCR is being evaluated in prospective clinical trials where it is incorporated into the post-consolidation care of patients with APL. The clinical utility of such an approach is uncertain. Such monitoring is likely only to be useful if done frequently with a planned intervention as soon as a positive signal is seen. For patients with APL, we consider patients to have relapsed disease if, after attainment of complete molecular remission, subsequent analyses confirm the loss of such molecular remission. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Use in APL'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H16#H16\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Monitoring response during maintenance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of MRD monitoring in patients with non-APL AML is less clear. Decisions on whether to continue, alter, or resume therapy cannot at present be based solely upon a positive signal with RT-PCR. The cut-off values examined in the published literature have been derived from retrospective analyses, and appropriate prospective validation is needed to confirm these results. The detection of cells from the leukemic clone is not, in itself, an indication that relapse is imminent. Such cells might be incapable of division or proliferation, might be able to divide but not mature, or might be held in check by the patient's immune system. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Use in non-APL AML'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/1\">",
"      D&ouml;hner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/2\">",
"      Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21:4642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/3\">",
"      de Greef GE, van Putten WL, Boogaerts M, et al. Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol 2005; 128:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/4\">",
"      Marcucci G, Mr&oacute;zek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol 2004; 22:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/5\">",
"      Chen Y, Cortes J, Estrov Z, et al. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol 2011; 29:2507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/6\">",
"      Appelbaum FR, Rosenblum D, Arceci RJ, et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 2007; 109:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/7\">",
"      Walter RB, Kantarjian HM, Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol 2010; 28:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/8\">",
"      Bloomfield CD, Shuma C, Regal L, et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 1997; 80:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/9\">",
"      Schiffer CA, Dodge R, Larson RA. Long-term follow-up of Cancer and Leukemia Group B studies in acute myeloid leukemia. Cancer 1997; 80:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/10\">",
"      Yanada M, Garcia-Manero G, Borthakur G, et al. Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. Cancer 2007; 110:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/11\">",
"      Frassoni F, Labopin M, Gluckman E, et al. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1994; 8:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/12\">",
"      Takagi S, Tanaka O. Magnetic resonance imaging of femoral marrow predicts outcome in adult patients with acute myeloid leukaemia in complete remission. Br J Haematol 2002; 117:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/13\">",
"      Cav&eacute; H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/14\">",
"      Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003; 121:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/15\">",
"      Kern W, Haferlach C, Haferlach T, Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 2008; 112:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/16\">",
"      Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol 2011; 153:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/17\">",
"      Diverio D, Pandolfi PP, Biondi A, et al. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 1993; 82:3556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/18\">",
"      Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/19\">",
"      Chomel JC, Brizard F, Veinstein A, et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood 2000; 95:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/20\">",
"      Lowdell MW, Craston R, Samuel D, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002; 117:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/21\">",
"      Hokland P, Ommen HB. Towards individualized follow-up in adult acute myeloid leukemia in remission. Blood 2011; 117:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/22\">",
"      Krauter J, Wattjes MP, Nagel S, et al. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. Br J Haematol 1999; 107:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/23\">",
"      Yin JA, Grimwade D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet 2002; 360:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/24\">",
"      Kern W, Voskova D, Schoch C, et al. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104:3078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/25\">",
"      Lo Coco F, Diverio D, Falini B, et al. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999; 94:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/26\">",
"      Buonamici S, Ottaviani E, Testoni N, et al. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/27\">",
"      Matsushita M, Ikeda H, Kizaki M, et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 2001; 112:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/28\">",
"      &Oslash;stergaard M, Olesen LH, Hasle H, et al. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 2004; 125:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/29\">",
"      Bachas C, Schuurhuis GJ, Hollink IH, et al. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood 2010; 116:2752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/30\">",
"      Muto A, Mori S, Matsushita H, et al. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. Br J Haematol 1996; 95:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/31\">",
"      Tobal K, Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21). Blood 1996; 88:3704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/32\">",
"      Schnittger S, Weisser M, Schoch C, et al. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102:2746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/33\">",
"      Krauter J, Gorlich K, Ottmann O, et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 2003; 21:4413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/34\">",
"      Dominietto A, Pozzi S, Miglino M, et al. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood 2007; 109:5063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/35\">",
"      Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010; 115:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/36\">",
"      Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009; 27:3650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/37\">",
"      Jurcic JG, Nimer SD, Scheinberg DA, et al. Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 2001; 98:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/38\">",
"      Gallagher RE, Yeap BY, Bi W, et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/39\">",
"      Chendamarai E, Balasubramanian P, George B, et al. Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. Blood 2012; 119:3413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/40\">",
"      Buccisano F, Maurillo L, Spagnoli A, et al. Monitoring of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2009; 21:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/41\">",
"      Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest 2000; 18:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/42\">",
"      Tobal K, Newton J, Macheta M, et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000; 95:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/43\">",
"      Satake N, Maseki N, Kozu T, et al. Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission. Br J Haematol 1995; 91:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/44\">",
"      Mitterbauer G, Zimmer C, Pirc-Danoewinata H, et al. Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction. Br J Haematol 2000; 109:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/45\">",
"      Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27:5195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/46\">",
"      Fang M, Storer B, Wood B, et al. Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Cancer 2012; 118:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/47\">",
"      Corbacioglu A, Scholl C, Schlenk RF, et al. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 2010; 28:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/48\">",
"      Kr&ouml;nke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011; 29:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/49\">",
"      Yin JA, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012; 120:2826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/50\">",
"      Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013; 121:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/51\">",
"      Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001; 97:3574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/52\">",
"      Sievers EL, Lange BJ, Alonzo TA, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003; 101:3398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/53\">",
"      Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003; 123:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/54\">",
"      Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96:3948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/55\">",
"      San Miguel JF, Vidriales MB, L&oacute;pez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/56\">",
"      Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008; 26:4944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/57\">",
"      Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011; 29:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/58\">",
"      Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010; 116:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/59\">",
"      Diverio D, Rossi V, Avvisati G, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter \"AIDA\" trial. GIMEMA-AIEOP Multicenter \"AIDA\" Trial. Blood 1998; 92:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/60\">",
"      Kizaki M, Ueno H, Matsushita H, et al. Retinoid resistance in leukemic cells. Leuk Lymphoma 1997; 25:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/61\">",
"      Delva L, Cornic M, Balitrand N, et al. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993; 82:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/62\">",
"      Kizaki M, Ueno H, Yamazoe Y, et al. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood 1996; 87:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/63\">",
"      Imaizumi M, Suzuki H, Yoshinari M, et al. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood 1998; 92:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12073/abstract/64\">",
"      Ding W, Li YP, Nobile LM, et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998; 92:1172.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4485 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12073=[""].join("\n");
var outline_f11_50_12073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22652924\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF COMPLETE REMISSION (CR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Other responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CR AS DEFINED BY LONG-TERM SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFICULTIES IN DEFINING CR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sampling error",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sensitivity of routine tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LIMITATIONS OF PCR AND FLOW CYTOMETRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Multiparameter flow cytometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SIGNIFICANCE OF RESIDUAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Detected by PCR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Use in APL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Use in non-APL AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Detected by flow cytometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RELAPSED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22652924\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4485\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4485|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/0/1038\" title=\"figure 1\">",
"      MRD inv16 AML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4485|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/5/1118\" title=\"table 1\">",
"      Response criteria AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/37/25179\" title=\"table 2\">",
"      Detection MRD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15880?source=related_link\">",
"      Detection of minimal residual disease in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=related_link\">",
"      General aspects of cytogenetic analysis in hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=related_link\">",
"      Treatment of relapsed or refractory acute myeloid leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_50_12074="Control of ventricular rate in atrial fibrillation: Pharmacologic therapy";
var content_f11_50_12074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/50/12074/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/50/12074/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/50/12074/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/50/12074/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/50/12074/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/50/12074/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/50/12074/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with atrial fibrillation (AF), the ventricular rate is controlled by the conduction properties of the atrioventricular (AV) node. In the typical patient with untreated AF, the ventricular rate can reach 150",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    or higher.",
"   </p>",
"   <p>",
"    There are two important reasons to prevent a rapid ventricular response in patients with AF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of hemodynamic instability",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link\">",
"       \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Avoidance of a tachycardia-mediated cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"       \"Tachycardia-mediated cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of pharmacologic therapies to achieve rate control in AF will be reviewed here. Nonpharmacologic therapies for rate control in AF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of patients with AF and a rapid ventricular response involves two decisions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determining the urgency of initial therapy (eg, intravenous versus oral rate control therapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immediate versus elective cardioversion).",
"     </li>",
"     <li>",
"      Choosing between a rate control and a rhythm control strategy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"       \"Rhythm control versus rate control in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These decisions are not independent, and the options are not mutually exclusive. As an example, a patient for whom rate control may be the appropriate long-term strategy may require urgent cardioversion in the acute setting due to hemodynamic instability. On the other hand, a patient for whom a chronic rhythm control strategy is chosen may require initial rate control for three to four weeks to permit appropriate anticoagulation prior to cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of atrial fibrillation\", section on 'Treatment issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a rate control strategy is chosen, most patients can be successfully managed with pharmacologic therapy. Selection of an appropriate regimen is guided by an understanding of the determinants of the ventricular rate in AF and a structured method for assessing the adequacy of rate control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Determinants of ventricular rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;During AF, electrical activity in the atria can exceed 400",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    The majority of these impulses do not conduct to the ventricles because of the electrical properties of the AV node. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=see_link&amp;anchor=H8804432#H8804432\">",
"     \"Mechanisms of atrial fibrillation\", section on 'Role of the atrioventricular node'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AV nodal tissue consists of so-called \"slow response\" fibers. In most myocardial tissue, the initial depolarizing phase of the action potential (phase 0) is mediated by rapid sodium channels. In contrast, in the slow response fibers of the AV node, phase 0 is mediated by an inward calcium current, which uses a kinetically slow channel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relatively slow kinetics of the inward calcium current limits conduction velocity through the AV node, and therefore the ventricular rate during AF. In addition to these intrinsic properties, the AV node is also richly supplied and affected by both components of the autonomic nervous system. AV conduction is enhanced by sympathetic fibers and slowed by parasympathetic fibers (",
"    <a class=\"graphic graphic_figure graphicRef75699 \" href=\"UTD.htm?38/48/39695\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the typical patient with untreated AF, the ventricular rate during the day varies between 90 and 170",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    The ventricular rate may be slower (eg, less than 60",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased vagal tone",
"     </li>",
"     <li>",
"      Drugs that affect AV nodal conduction",
"     </li>",
"     <li>",
"      AV nodal disease, which should be suspected if the ventricular rate is below 60",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      in the absence of a drug that slows AV conduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A ventricular rate above 200",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    suggests one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Catecholamine excess",
"     </li>",
"     <li>",
"      Parasympathetic withdrawal",
"     </li>",
"     <li>",
"      Hyperthyroidism",
"     </li>",
"     <li>",
"      An accessory pathway as occurs in the preexcitation syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"       \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rate control goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal rate goal for patients with AF has not been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/1\">",
"     1",
"    </a>",
"    ]. Achieving rates similar to those recommended for patients in sinus rhythm with heart disease has been advocated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/2\">",
"     2",
"    </a>",
"    ]: resting heart rate &le;80",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    and &le;110",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    during moderate exercise such as with the six minute walk. Goals similar to these were used in many of the trials of rate versus rhythm control, such as AFFIRM [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This issue was directly addressed in the RACE II trial, which randomly assigned 614 physically active patients with permanent AF to either a lenient rate control strategy (resting heart rate &lt;110 beats per minute) or a strict rate control strategy (resting heart rate &lt;80 beats per minute and heart rate during moderate exercise &lt;110 beats per minute) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/4\">",
"     4",
"    </a>",
"    ]. The primary outcome was a composite of cardiovascular death, hospitalization for heart failure, and stroke, systemic embolism, bleeding, and life-threatening arrhythmic events. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With regard to the three year estimated cumulative incidence of the primary outcome, lenient control was non-inferior to strict rate control (12.9 versus 14.9 percent respectively; hazard ratio 0.84; 90% CI 0.58-1.21).",
"     </li>",
"     <li>",
"      In the lenient and strict rate control groups, 98 and 75 percent of patients respectively met their resting heart rate target. This target required use of more than one rate slowing (atrioventricular blocking) in 30 and 69 percent of patients respectively. When the data were analyzed from the end of the dose-adjustment phase until the end of follow-up (median 2.9 years), the average heart rates in the lenient control group, strict control group patients who met the target, and strict control group patients who failed to meet the target were significantly different at 93, 72, and 86 beats per minute, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/5\">",
"       5",
"      </a>",
"      ]. However, there was no significant difference in the primary outcome (12.1 versus 14.2 versus 15 percent).",
"     </li>",
"     <li>",
"      There were nearly nine times as many visits (684 versus 75) to achieve rate the control target(s) in those assigned to strict control. Rate control was &ldquo;stricter&rdquo; than anticipated in the lenient control group. Though the target rate was less than 110 beats per minute at rest, mean resting rates in this group at the after 1 year, 2 years, and at the end of follow-up were 86+15, 84+14, and 85+14 beats per minute, respectively. By comparison, mean resting rates in the strict control group were 75+12, 75+12, and 76+14 beats per minute, respectively. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the results of the RACE II trial, we believe that achieving strict heart rate control is not necessary in many physically active patients with AF who are minimally symptomatic. A more lenient rate control strategy offers the advantages of less medication (fewer drug side effects, lower cost) and fewer outpatient visits to achieve heart rate control.",
"   </p>",
"   <p>",
"    The prevention of symptoms during normal activities or exercise is a primary goal of therapy. It is important to consider that symptoms may be due to either inadequate rate control or relative bradycardia (eg, in patients with tachy-brady syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link&amp;anchor=H5#H5\">",
"     \"Manifestations and causes of the sick sinus syndrome\", section on 'Tachycardia-bradycardia syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, for those patients in whom a lenient strategy is chosen but who remain symptomatic, an attempt should be made to decrease symptoms by setting a lower rate goal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Documenting rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;In practice the efficacy of heart rate control therapy can be assessed by measurement of both the resting heart rate and use of either a six minute walk test (at moderate exercise) or submaximal or maximal exercise ECG testing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/2\">",
"     2",
"    </a>",
"    ]. A 24-hour ambulatory monitor can also be used to evaluate efficacy. For young active patients, we recommend either an exercise ECG test or a Holter during exercise. For older or sedentary patients, measuring heart rate after walking briskly around the office or up stairs may provide sufficient information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H537237617\">",
"    <span class=\"h3\">",
"     Tachycardia-mediated cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistently increased ventricular rates in AF have been associated with a left ventricular cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While this issue has not been well studied, we believe that this phenomenon is unlikely to occur if the ventricular rate is kept below 110",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    which is the recommended heart rate goal. Some experts perform an echocardiogram every two to three years in asymptomatic patients with higher average ventricular rates while others do not. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Urgency of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient with new or recurrent AF with a rapid ventricular response, the intensity of initial therapy depends upon the clinical scenario:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emergent therapy &mdash; In patients who are clinically or hemodynamically unstable (eg, myocardial ischemia, pulmonary edema, hypotension) due to AF and a rapid ventricular response, treatment options include intravenous rate control medications",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immediate cardioversion (",
"      <a class=\"graphic graphic_table graphicRef72962 \" href=\"UTD.htm?12/49/13084\">",
"       table 1",
"      </a>",
"      ). In patients with an adequate blood pressure, pharmacologic rate control with intravenous calcium channel blockers or beta blockers may be attempted, while arrangements are made for cardioversion. If the patient responds to rate control therapy but remains unstable, an explanation other than AF with a rapid ventricular response should be sought. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urgent therapy &mdash; In patients with AF and a rapid ventricular response who are symptomatic but not unstable, initial therapy usually involves intravenous rate control medications. Patients who are chronically managed with a rhythm control strategy can undergo cardioversion if they have been adequately anticoagulated or are considered to have a low thromboembolic risk.",
"     </li>",
"     <li>",
"      Elective therapy &mdash; Patients who have mild or no symptoms, and whose ventricular rate is mildly to moderately elevated (eg, &le;120",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      can be managed with the addition or increase of oral rate control medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rhythm versus rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main therapeutic strategies in patients with AF are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rhythm control, which consists of cardioversion, often followed by maintenance of sinus rhythm with arrhythmic drugs.",
"     </li>",
"     <li>",
"      Rate control, usually with drugs that slow conduction through the AV node.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, many physicians preferred a rhythm control strategy because of presumed improvements in symptoms, hemodynamics, and embolic risk. However, the expected advantages of rhythm control were not confirmed in AFFIRM, RACE, and other randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. As a result, a rate control strategy is now preferred in most asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The data supporting this conclusion are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Caution in preexcitation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with AF and preexcitation, initial therapy is aimed at reversion to sinus rhythm. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    should be given if hemodynamics are stable, and DC cardioversion should be performed if the patient is unstable.",
"   </p>",
"   <p>",
"    The AV nodal blocking drugs (calcium channel blockers, beta blockers, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ) can",
"    <strong>",
"     paradoxically increase",
"    </strong>",
"    the ventricular response in patients with AF and preexcitation by impairing conduction via the normal AV node-His-Purkinje system. This decreases retrograde concealed conduction in the accessory pathway, thereby improving antegrade conduction over the pathway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link&amp;anchor=H11#H11\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\", section on 'Avoidance of AV nodal blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term therapy in preexcited AF includes ablation of the accessory pathway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ventricular rate in atrial fibrillation is slowed using beta blockers or calcium channel blockers, and to a lesser extent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . These agents slow atrioventricular (AV) nodal conduction based upon the following physiologic mechanisms (",
"    <a class=\"graphic graphic_figure graphicRef51932 \" href=\"UTD.htm?6/18/6446\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blockade of the calcium channel with the nondihydropyridine calcium channel blockers",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Decreased sympathetic tone resulting from beta blockers.",
"     </li>",
"     <li>",
"      Enhancement of parasympathetic tone with vagotonic drugs, the most important of which is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are commonly used for both the acute and chronic control of ventricular rates in patients with AF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Acute control with beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the acute control of ventricular rate, intravenous beta blockade with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    can be effective. Beta blockers may be particularly useful in states of high adrenergic tone (eg, postoperative AF).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     Metoprolol",
"    </a>",
"    is given as an intravenous bolus of 2.5 to 5.0 mg over two minutes. The dose may be repeated at five minute intervals up to a total of 15 mg as needed. While subsequent doses can be given intravenously, the optimal regimen is not well defined, and oral administration is preferable.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     Esmolol",
"    </a>",
"    is a rapidly acting intravenous beta blocker that is metabolized by red blood cell esterase, resulting in a short duration of action (10 to 20 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Esmolol may be particularly useful if it is uncertain that a beta blocker will be tolerated, since its short half-life permits a therapeutic trial to be performed at reduced risk. If esmolol is tolerated, then a long-acting beta blocker can be given.",
"   </p>",
"   <p>",
"    The following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    regimen is recommended for acute rate control:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A bolus of 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      is infused over one minute, followed by 50",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min.",
"     </li>",
"     <li>",
"      If, after four minutes, the response is inadequate, another bolus is given followed by an infusion of 100",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min.",
"     </li>",
"     <li>",
"      If, after four minutes, the response is still inadequate, a third and final bolus can be given followed by an infusion of 150",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min.",
"     </li>",
"     <li>",
"      If necessary, the infusion can be increased to a maximum of 200",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min after another four minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, an infusion can be started at 50",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min without a bolus, and the rate of administration can be increased by 50",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min every 30 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Chronic beta blocker therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral beta blockers are widely used as primary therapy for rate control in chronic AF (",
"    <a class=\"graphic graphic_table graphicRef82571 \" href=\"UTD.htm?14/26/14766\">",
"     table 2",
"    </a>",
"    ). Beta blockers decrease the resting heart rate and blunt the heart rate response to exercise. Most beta blockers appear to have similar efficacy, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"     timolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    have the most supporting evidence. There are some data that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    is less effective than other beta blockers for reducing HR at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     Atenolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    have the advantages of a long half-life and are typically given once daily. In our experience, atenolol has the additional advantage of producing less central nervous system side effects than other beta blockers. Long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    preparations are also effective if tolerated. We generally begin with 25 mg of atenolol per day and gradually increase the daily dose to 100 mg, and sometimes 200 mg, if necessary.",
"   </p>",
"   <p>",
"    Beta blockers have additional properties that may make them preferred to other rate control drugs in some AF patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with chronic heart failure due to systolic dysfunction &mdash; A retrospective analysis from the US",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       Carvedilol",
"      </a>",
"      Trials Program evaluated 1094 heart failure patients with AF [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/14\">",
"       14",
"      </a>",
"      ]. In this population, carvedilol therapy led to a statistically significant improvement in left ventricular ejection fraction. In addition, there was a trend toward a decrease in the combined end point of death or hospitalization for heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"       \"Atrial fibrillation in patients with heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beta blockers may reduce the incidence of AF recurrence in patients with episodes of AF that are triggered by surges in sympathetic activity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beta blockers also have a variety of adverse effects. Some of these complications that may be important in patients with AF include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Worsening heart failure",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Bronchospasm",
"     </li>",
"     <li>",
"      Reduced exercise tolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High-degree AV block",
"     </li>",
"     <li>",
"      Bradycardia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with paroxysmal AF also have sinus node dysfunction, with the tachycardia-bradycardia syndrome. In such patients, beta blockers with intrinsic sympathomimetic activity may be useful since they are less likely to worsen bradycardia than standard beta blockers (",
"    <a class=\"graphic graphic_table graphicRef82571 \" href=\"UTD.htm?14/26/14766\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link&amp;anchor=H5#H5\">",
"     \"Manifestations and causes of the sick sinus syndrome\", section on 'Tachycardia-bradycardia syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nondihydropyridine calcium channel blockers",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    are useful in the management of AF in the absence of pre-excitation. These drugs can be used intravenously for acute rate control and can produce long-term rate slowing when used orally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39831?source=see_link\">",
"     \"Calcium channel blockers in the treatment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      increases refractoriness and decreases conduction velocity in the AV node [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/18-25\">",
"       18-25",
"      </a>",
"      ] Although it is often used in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , monotherapy with oral verapamil is often possible [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       Diltiazem",
"      </a>",
"      may have a less pronounced negative inotropic effect than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/26\">",
"       26",
"      </a>",
"      ]. The intravenous preparation is effective for acute control of the ventricular rate in AF [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/27-29\">",
"       27-29",
"      </a>",
"      ], while oral therapy is effective for chronic rate control [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Acute control with calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    can be given acutely in a dose of 5 to 10 mg over two to three minutes; this dose can be repeated every 15 to 30 minutes, as necessary. The maintenance infusion rate is approximately 0.125",
"    <span class=\"nowrap\">",
"     mg/min.",
"    </span>",
"    The onset of action is within two minutes and the peak effect occurs in 10 to 15 minutes. Control of the ventricular response is lost in approximately 90 minutes if repeated boluses or a maintenance infusion are not given.",
"   </p>",
"   <p>",
"    The suggested regimen for intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    is derived from the Diltiazem Atrial",
"    <span class=\"nowrap\">",
"     Fibrillation/Atrial",
"    </span>",
"    Flutter Study Group [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Diltiazem is given as an intravenous bolus of 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (average adult dose 20 mg) over two minutes; in 15 minutes, if the first dose is tolerated but does not produce the desired response (20 percent reduction in heart rate from the baseline or a heart rate less than or equal to 100",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    a second bolus of 0.35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (average adult dose 25 mg) is given over two minutes; in those who respond to the first or second bolus, a continuous infusion at a rate of 5 to 15",
"    <span class=\"nowrap\">",
"     mg/h",
"    </span>",
"    is initiated. This regimen usually controls the ventricular rate within four to five minutes.",
"   </p>",
"   <p>",
"    The efficacy of this regimen was evaluated in a report of 84 consecutive patients with AF, atrial flutter, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/29\">",
"     29",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall response rate was 94 percent.",
"     </li>",
"     <li>",
"      The continuous infusion maintained adequate rate control for 10 hours or longer in a dose-dependent fashion &mdash; 47 percent at 5",
"      <span class=\"nowrap\">",
"       mg/h;",
"      </span>",
"      68 percent after titration to 10",
"      <span class=\"nowrap\">",
"       mg/h;",
"      </span>",
"      and 76 percent after titration to 15",
"      <span class=\"nowrap\">",
"       mg/h",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef80630 \" href=\"UTD.htm?15/21/15709\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hypotension occurred in 13 percent and was symptomatic in almost 4 percent. All such patients responded to isotonic saline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chronic calcium channel blocker therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    is 40 mg three or four times per day increased to a maximum of 360",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses. The equivalent dose of sustained release verapamil can be used once per day, but a divided dose often must be used to maintain rate control.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    is started at 30 mg four times daily. The usual maximum dose is a total of 360 to 480 mg daily (ie, 90 to 120 mg four times per day). For conversion to the sustained release form of diltiazem, the same total daily dose is given in a single tablet or divided into two doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Clinical cautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers have a number of characteristics that need to be considered with when they are administered to patients with AF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effect on sinoatrial (SA) nodal function is variable. Although both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      have an inhibitory effect on the sinus node, their vasodilator effects cause a reflex release of catecholamines that usually maintains or slightly accelerates the SA nodal rate. However, patients with the sick sinus syndrome may be particularly sensitive to the effects of calcium channel blockers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=see_link\">",
"       \"Manifestations and causes of the sick sinus syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      have negative inotropic effects, although this is less pronounced with diltiazem. As a result, these drugs should be used with caution in patients with heart failure and in patients taking other negative inotropes, such as beta blockers. They should not be given if the patient is hypotensive.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      interacts with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , resulting in an increase in serum digoxin. This interaction is dose-related (often occurring when verapamil doses are over 240",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      and generally occurs after seven days of therapy with both agents. Similar to the digoxin-quinidine interaction, verapamil reduces the renal clearance of digoxin; it may also interfere with its hepatic metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/32-34\">",
"       32-34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , it should be remembered that older patients are more likely to develop side effects, especially cardiac. Although the same maximum doses may be tolerated, it is usually appropriate to titrate more slowly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be given to patients with severe heart failure (NYHA class III or IV), the preexcitation syndrome, or significant hypotension. In addition, these drugs should be given with caution to patients with sinus node dysfunction, significant liver disease, mild hypotension, marked first-degree heart block, or the concurrent intake of other drugs that inhibit SA nodal function or slow AV nodal conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    slows the ventricular rate during AF primarily by vagotonic inhibition of AV nodal conduction. Digoxin is generally less effective for rate control than beta blockers or calcium channel blockers, particularly during exercise when vagal tone is low and sympathetic tone is high (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Comparative efficacy'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/11,18,19,35-40\">",
"     11,18,19,35-40",
"    </a>",
"    ]. Furthermore, digoxin has no ability to terminate AF.",
"   </p>",
"   <p>",
"    For these reasons,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    should not be used as a first-line drug for rate control in most settings [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/2,37,41\">",
"     2,37,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HF due to systolic dysfunction and AF,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    has two potential benefits; reduction in the ventricular rate and improvement in contractility. For these reasons, digoxin was in the past considered a reasonable first-line therapy for rate control in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/37,41\">",
"     37,41",
"    </a>",
"    ]. However, beta blockers, if tolerated, are now a standard component of therapy for all patients with HF due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, in patients with left ventricular dysfunction, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is limited to the following settings (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who do not achieve rate control targets on beta blockers alone.",
"     </li>",
"     <li>",
"      Patients who cannot tolerate the addition of or increased doses of a beta blocker due to acute decompensated HF.",
"     </li>",
"     <li>",
"      Patients in whom",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      would be added for improved control of HF symptoms independent of AF. Many such patients will already be treated with a beta blocker, and care must be taken to avoid excessive bradycardia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link&amp;anchor=H16#H16\">",
"       \"Use of digoxin in heart failure due to systolic dysfunction\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Dosing and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    can be administered orally, intravenously, or intramuscularly, although we do not use the intramuscular route because absorption is erratic. Intravenous digoxin begins to act within 15 to 30 minutes, with a peak effect attained in one to five hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=see_link\">",
"     \"Treatment with digoxin: initial dosing, monitoring, and dose modification\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    levels should be monitored periodically. Although the correlation between drug concentration and ventricular rate control is poor, the presence of a low serum digoxin concentration is useful in that it allows a higher dose to be administered.",
"   </p>",
"   <p>",
"    Junctional escape beats (detected by the equality of all of the longest observed R-R intervals on the electrocardiogram) are common when digitalis has successfully slowed the ventricular rate. Giving more",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    in this setting will increase the degree of AV nodal block and produce periods of a regular junctional escape rhythm. The change from single junctional escapes to periodic junctional rhythm usually signifies the development of digoxin toxicity. AF with a slow, regular ventricular response generally reflects complete AV block, which may be due to digoxin excess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link&amp;anchor=H7983933#H7983933\">",
"     \"The electrocardiogram in atrial fibrillation\", section on 'Effect of high degrees of AV nodal block and exit block on ventricular response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is commonly used to maintain sinus rhythm in AF patients in whom a rhythm control strategy is chosen. However, amiodarone can also slow the ventricular rate in patients who remain in AF. In one study, for example, intravenous amiodarone (7",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , or placebo was given to 98 patients with recent onset AF (0.5 to 72 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/42\">",
"     42",
"    </a>",
"    ]. Even when AF did not revert to sinus rhythm, amiodarone promptly slowed the ventricular rate during the eight hour observation period (",
"    <a class=\"graphic graphic_figure graphicRef81119 \" href=\"UTD.htm?13/17/13598\">",
"     figure 4",
"    </a>",
"    ). In addition, in critically ill patients, amiodarone may be less likely to cause systemic hypotension than intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the long-term risk of side effects, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines on AF concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is a second-line therapy for chronic rate control that can be considered when beta blockers and calcium channel blockers, alone, combined, or when used with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , are ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Magnesium sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnesium has physiologic properties suggesting that it might have efficacy for rate control in AF. Initial small studies provided the rationale for a clinical trial in which 199 patients presenting with rapid AF (mean baseline ventricular rate 142 beats per min) were treated with usual therapy for rate control, most often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and randomly assigned to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    (2.5 g over 20 minutes followed by 2.5 g over two hours) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/44\">",
"     44",
"    </a>",
"    ]. Magnesium therapy increased the likelihood of achieving a ventricular rate &lt;100",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    (65 versus 34 percent with placebo) and conversion to sinus rhythm (27 versus 12 percent with placebo). However, the difference in mean ventricular rate never exceeded 12",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"   </p>",
"   <p>",
"    Important",
"    limitations to the results of study include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefit of magnesium was modest.",
"     </li>",
"     <li>",
"      Preferred primary therapies (calcium channel blocker, beta blocker) were used in only 12 to 13 percent of the patients.",
"     </li>",
"     <li>",
"      Magnesium was associated with side effects such as flushing and hypotension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMPARATIVE EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies directly comparing the efficacy of these drugs. In general, calcium channel blockers are effective at rest and during exercise, beta blockers are similarly effective at rest, but more effective during exercise, and digitalis is reasonably effective at rest but less effective than the other drugs during exercise. Thus, it is particularly important to assess HR with exertion in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    alone.",
"   </p>",
"   <p>",
"    In a small crossover study of 12 patients with chronic AF, patients were treated for two week intervals with five different drug regimens:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    0.25 mg daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    -CD 240 mg daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    50 mg daily, digoxin plus diltiazem, and digoxin plus atenolol [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/35\">",
"     35",
"    </a>",
"    ]. Digoxin plus atenolol was the most effective regimen for controlling the mean ventricular rate and reducing the peak heart rate during exercise; digoxin and diltiazem as single agents were the least effective (",
"    <a class=\"graphic graphic_figure graphicRef73989 \" href=\"UTD.htm?2/22/2400\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     AFFIRM trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among evaluations of rate control drugs, the study with the largest sample size and longest follow-up is a post-hoc analysis from the AFFIRM trial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/45\">",
"     45",
"    </a>",
"    ]. In AFFIRM, which compared rate control and rhythm control strategies, 2027 patients were randomly assigned to the rate control arm. Adequate rate control at rest and exercise was defined according to predetermined criteria (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Rate control goals'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The overall effectiveness (meeting both rest and exertion goals) of initial therapy was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beta blocker alone &mdash; 59 percent",
"     </li>",
"     <li>",
"      Calcium channel blocker alone &mdash; 38 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      alone &mdash; 58 percent",
"     </li>",
"     <li>",
"      Beta blocker plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      &mdash; 68 percent",
"     </li>",
"     <li>",
"      Calcium channel blocker plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      &mdash; 60 percent",
"     </li>",
"     <li>",
"      Beta blocker plus calcium channel blocker &mdash; 59 percent",
"     </li>",
"     <li>",
"      Beta blocker plus calcium channel blocker plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      &mdash; 76 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At five years follow-up, adequate rate control increased from approximately 60 to 80 percent of patients. Only 58 percent of patients had adequate rate control with the first drug or combination used. Patients initially treated with a beta blocker were significantly less likely than those treated with calcium channel blockers or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    to have their drug regimen changed.",
"   </p>",
"   <p>",
"    Several important limitations to this study need to be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once randomized to the rate control arm of the trial, drug selection was not randomized. There were significant differences between patients treated with different regimens; beta blockers were more commonly used in patients with coronary disease, calcium channel blockers were more often given to patients with pulmonary disease and to women, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      was used more often in patients with cardiomyopathy and in nonwhite patients. Whether these baseline differences had an impact on the adequacy of rate control is not known.",
"     </li>",
"     <li>",
"      Only 361 (18 percent) of the patients assigned to the rate control strategy had an initial assessment of the adequacy of rate control at rest and with exertion. This is because many patients spontaneously reverted to sinus rhythm (and therefore, rate control could not be assessed), and also because of the limited number of patients in AF who had HR assessed with exertion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Systematic review",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review on the overall management of AF included a discussion of 54 trials that evaluated 17 different agents used for rate control [",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/8\">",
"     8",
"    </a>",
"    ]. The studies were all relatively small (6 to 239 patients), and had follow-up periods of 8 weeks or less. Most compared single agents to placebo. Due to extensive variability in methods and outcome assessments, a summary analysis of the trials could not be performed. However, the following observations were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       Diltiazem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , and most beta blockers (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"       timolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"       pindolol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       nadolol",
"      </a>",
"      ) were all effective in reducing the ventricular rate during rest and exercise. The beta blockers",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      , xamoterol and celiprolol were less effective at rest, but did reduce ventricular rates during exercise.",
"     </li>",
"     <li>",
"      Trials comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      to placebo reported inconsistent results, particularly when HR during exercise was assessed.",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      with a beta blocker or calcium channel blocker reduced HR both at rest and with exertion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, pharmacologic therapy can achieve adequate rate control in approximately 80 percent of patients. However, achieving this goal requires close monitoring, medication adjustments and often combination therapy. Although there are differences in the efficacy of the various drugs, it is likely that monitoring and adjustments to therapy are more important components of successful rate control strategies than is the initial drug selection (",
"    <a class=\"graphic graphic_algorithm graphicRef75491 \" href=\"UTD.htm?25/27/26046\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/36/17986?source=see_link\">",
"       \"Patient information: Medicines for atrial fibrillation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations are in general agreement with the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines on atrial fibrillation&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This discussion applies to AF patients in whom a chronic rate control strategy has been chosen, or to any AF patient requiring acute rate control. A discussion of the relative risks and benefits of rate versus rhythm control strategies is presented in detail separately. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Rhythm versus rate control'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Acute rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with AF and a rapid ventricular response, acute HR control is usually achieved with intravenous medications. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Urgency of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In such patients, we suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients without significant heart failure or hypotension, we suggest intravenous beta blockers or nondihydropyridine calcium channel blockers&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Acute control with beta blockers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Acute control with calcium channel blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , using the regimen described above, is our preferred drug in this setting. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Acute control with calcium channel blockers'",
"      </a>",
"      above.) However, comparative data are limited and intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or intravenous beta blockers such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"       esmolol",
"      </a>",
"      are reasonable alternatives (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Comparative efficacy'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/50/12074/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If it is uncertain whether such therapy will be tolerated by the patient,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"       esmolol",
"      </a>",
"      may be cautiously administered since its very short half-life permits a therapeutic trial to be performed at reduced risk (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Acute control with beta blockers'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In patients who do not adequately respond to initial therapy with either an intravenous beta blocker or intravenous calcium channel blocker, we suggest the addition of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      as the second drug in combination therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Digoxin'",
"      </a>",
"      above.) Some patients have a greater degree of rate control with a beta blocker than with a calcium channel blocker, and vice versa. Thus, in patients who have an inadequate response to one of these drugs, switching to a drug from the other class is an alternative to adding digoxin.",
"      <br/>",
"      <br/>",
"      If rate control is achieved, we try to use the second drug as a single agent and to avoid using beta blockers and calcium channel blockers as combination therapy for rate control. However, in selected patients who do not have hypotension or significant left ventricular dysfunction, these classes may be used together, and in some cases all three agents (ie, a beta blocker, a calcium channel blocker, and digoxin) may be necessary to achieve adequate rate control.",
"     </li>",
"     <li>",
"      In patients with advanced HF or significant hypotension, we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Digoxin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not respond to or are intolerant of intravenous calcium channel blockers, beta blockers,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      for acute control of the ventricular rate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Amiodarone'",
"      </a>",
"      above.) In such patients, the use of amiodarone for rate control is a short-term strategy (eg, hours to days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Chronic rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using drugs that block atrioventricular conduction, at least 75 percent of AF patients can achieve a rate control target of &le;80",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    and over 90 percent a target (&le;110",
"    <span class=\"nowrap\">",
"     beats/min).",
"    </span>",
"    However, achieving this goal requires close monitoring, medication adjustments and often combination therapy. In such patients, adjustments can often be made in the outpatient setting. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Urgency of therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Rate control goals'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although there are differences in the efficacy of the various drugs used for rate control, it is likely that monitoring and adjustments to therapy are more important components of successful rate control strategies than is the initial drug selection (",
"    <a class=\"graphic graphic_algorithm graphicRef75491 \" href=\"UTD.htm?25/27/26046\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest a lenient rate control goal of &lt;110",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      compared to a stricter rate control goal of &lt;80",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      for patients in atrial fibrillation in whom a rate control strategy has been chosen (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients who continue with unacceptable symptoms at this goal, an attempt should be made to see if a lower goal lessens symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Rate control goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who require chronic rate control therapy, we suggest initial therapy with an oral beta blocker or nondihydropyridine calcium channel blockers (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Chronic beta blocker therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Chronic calcium channel blocker therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Beta blockers are preferred in patients with coronary heart disease, heart failure due to systolic dysfunction, and in patients in whom the ventricular rate increases inappropriately during exercise. In the first two settings, beta blockers improve patient survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"       \"Beta blockers in the management of acute coronary syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Despite these advantages, beta blockers are contraindicated or relatively contraindicated in some patients, and others cannot tolerate the side effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"       \"Major side effects of beta blockers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A nondihydropyridine calcium channel blocker is preferred in patients with chronic lung disease and in patients who do not tolerate a beta blocker. Among the calcium channel blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      has a somewhat greater blocking effect on the AV node than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , and the choice between these drugs is often dictated by side effects. Diltiazem may be preferred in patients with mild heart failure if a beta blocker is contraindicated or not tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not achieve adequate rate control with a single agent, combination therapy should be used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who have inadequate rate control on maximum tolerated doses of either a beta blocker or a calcium channel blocker, we suggest the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      as the second agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Digoxin'",
"      </a>",
"      above.) The effect of digoxin is additive to both beta blockers and calcium channel blockers (",
"      <a class=\"graphic graphic_figure graphicRef73989 \" href=\"UTD.htm?2/22/2400\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients who do not achieve adequate rate control on maximum tolerated doses or either a beta blocker or a calcium channel blocker plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , we suggest adding a third agent from the class of drugs not yet included (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who are not adequately controlled on a beta blocker plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      should be added.",
"     </li>",
"     <li>",
"      For patients who are not adequately controlled on a calcium channel blocker plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , a beta blocker should be added.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although some patients may not tolerate both a beta blocker and a calcium channel blocker (eg, those with left ventricular systolic dysfunction or hypotension), the combination can be tried in most patients. As an alternative, patients who appear unlikely to tolerate both a beta blocker and calcium channel blocker, can be switched from one class to the other before trying both in combination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with AF who are at high risk for thromboembolic events we recommend chronic anticoagulation therapy unless there is a contraindication, regardless of whether they are treated with a rhythm control, pharmacologic rate control, or nonpharmacologic rate control strategy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients will not achieve adequate HR control with pharmacologic therapy due to poor response to or intolerance of the medications. In such cases, options include reconsideration of a rhythm control strategy and nonpharmacologic therapies to control the ventricular rate (",
"    <a class=\"graphic graphic_algorithm graphicRef75491 \" href=\"UTD.htm?25/27/26046\">",
"     algorithm 1",
"    </a>",
"    ). These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/1\">",
"      Dorian P. Rate control in atrial fibrillation. N Engl J Med 2010; 362:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/2\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/3\">",
"      Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/4\">",
"      Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/5\">",
"      Groenveld HF, Tijssen JG, Crijns HJ, et al. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol 2013; 61:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/6\">",
"      Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/7\">",
"      Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/8\">",
"      McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/9\">",
"      Pritchett EL. Management of atrial fibrillation. N Engl J Med 1992; 326:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/10\">",
"      Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation. J Am Coll Cardiol 1993; 22:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/11\">",
"      Shettigar UR, Toole JG, Appunn DO. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter. Am Heart J 1993; 126:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/12\">",
"      Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989; 63:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/13\">",
"      Schwartz M, Michelson EL, Sawin HS, MacVaugh H 3rd. Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias. Chest 1988; 93:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/14\">",
"      Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001; 142:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/15\">",
"      Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990; 63:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/16\">",
"      DiBianco R, Morganroth J, Freitag JA, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J 1984; 108:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/17\">",
"      Atwood JE, Sullivan M, Forbes S, et al. Effect of beta-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 1987; 10:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/18\">",
"      Klein HO, Pauzner H, Di Segni E, et al. The beneficial effects of verapamil in chronic atrial fibrillation. Arch Intern Med 1979; 139:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/19\">",
"      Panidis IP, Morganroth J, Baessler C. Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol 1983; 52:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/20\">",
"      Tommaso C, McDonough T, Parker M, Talano JV. Atrial fibrillation and flutter. Immediate control and conversion with intravenously administered verapamil. Arch Intern Med 1983; 143:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/21\">",
"      Hwang MH, Danoviz J, Pacold I, et al. Double-blind crossover randomized trial of intravenously administered verapamil. Its use for atrial fibrillation and flutter following open heart surgery. Arch Intern Med 1984; 144:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/22\">",
"      Waxman HL, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. Ann Intern Med 1981; 94:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/23\">",
"      Stern EH, Pitchon R, King BD, et al. Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. Chest 1982; 81:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/24\">",
"      Lang R, Klein HO, Weiss E, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 1983; 83:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/25\">",
"      Lundstr&ouml;m T, Ryd&eacute;n L. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 1990; 16:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/26\">",
"      B&ouml;hm M, Schwinger RH, Erdmann E. Different cardiodepressant potency of various calcium antagonists in human myocardium. Am J Cardiol 1990; 65:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/27\">",
"      Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group. Am J Cardiol 1989; 63:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/28\">",
"      Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol 1991; 18:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/29\">",
"      Ellenbogen KA, Dias VC, Cardello FP, et al. Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter. Am J Cardiol 1995; 75:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/30\">",
"      Steinberg JS, Katz RJ, Bren GB, et al. Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol 1987; 9:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/31\">",
"      Roth A, Harrison E, Mitani G, et al. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 1986; 73:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/32\">",
"      Klein HO, Lang R, Weiss E, et al. The influence of verapamil on serum digoxin concentration. Circulation 1982; 65:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/33\">",
"      Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993; 266:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/34\">",
"      Hedman A, Angelin B, Arvidsson A, et al. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 1991; 49:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/35\">",
"      Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/36\">",
"      Beasley R, Smith DA, McHaffie DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J (Clin Res Ed) 1985; 290:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/37\">",
"      Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med 1991; 114:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/38\">",
"      David D, Segni ED, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol 1979; 44:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/39\">",
"      Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000; 49:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/40\">",
"      Khalsa A, Edvardsson N, Olsson SB. Effects of metoprolol on heart rate in patients with digitalis treated chronic atrial fibrillation. Clin Cardiol 1978; 1:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/41\">",
"      Sarter BH, Marchlinski FE. Redefining the role of digoxin in the treatment of atrial fibrillation. Am J Cardiol 1992; 69:71G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/42\">",
"      Donovan KD, Power BM, Hockings BE, et al. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 1995; 75:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/43\">",
"      Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001; 29:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/44\">",
"      Davey MJ, Teubner D. A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation. Ann Emerg Med 2005; 45:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/45\">",
"      Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004; 43:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/50/12074/abstract/46\">",
"      Tamariz LJ, Bass EB. Pharmacological rate control of atrial fibrillation. Cardiol Clin 2004; 22:35.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 938 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12074=[""].join("\n");
var outline_f11_50_12074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Determinants of ventricular rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rate control goals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Documenting rate control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H537237617\">",
"      - Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Urgency of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rhythm versus rate control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Caution in preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHARMACOLOGIC TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Acute control with beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Chronic beta blocker therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Acute control with calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chronic calcium channel blocker therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Clinical cautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Digoxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Dosing and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMPARATIVE EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      AFFIRM trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Systematic review",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Acute rate control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Chronic rate control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/938\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/938|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/27/26046\" title=\"algorithm 1\">",
"      Rx chronic AF rate control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/938|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/48/39695\" title=\"figure 1\">",
"      AV nodal physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/18/6446\" title=\"figure 2\">",
"      Drug effect on AV node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/21/15709\" title=\"figure 3\">",
"      Dose response to diltiazem for rate control in AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/17/13598\" title=\"figure 4\">",
"      Efficacy of amiodarone and flecainide in AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/22/2400\" title=\"figure 5\">",
"      Comparison AV nodal blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/938|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/49/13084\" title=\"table 1\">",
"      Electrical cardioversion AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/26/14766\" title=\"table 2\">",
"      Properties beta blockers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39831?source=related_link\">",
"      Calcium channel blockers in the treatment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22008?source=related_link\">",
"      Manifestations and causes of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12266?source=related_link\">",
"      Mechanisms of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/36/17986?source=related_link\">",
"      Patient information: Medicines for atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=related_link\">",
"      Treatment with digoxin: initial dosing, monitoring, and dose modification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_50_12075="Therapeutic roles for hyperbaric oxygen";
var content_f11_50_12075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapeutic roles for hyperbaric oxygen",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Air or gas embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbon monoxide poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decompression sickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clostridial myonecrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crush injury and other forms of traumatic ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enhanced healing of problematic wounds, including diabetic wounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Actinomycotic brain abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Necrotizing soft tissue infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refractory osteomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation necrosis of soft tissue and bone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Compromised skin grafts and flaps",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12075=[""].join("\n");
var outline_f11_50_12075=null;
var title_f11_50_12076="CAM resources";
var content_f11_50_12076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complementary and alternative medicine resources for pediatric health care providers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Books",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Kemper KJ. \"The Holistic Pediatrician.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HarperCollins. 2002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Rakel D. \"Integrative Medicine.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saunders. 2012",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Loo M. \"Integrative Medicine for Children.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saunders. 2008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Culbert T, Olness K. \"Integrative Pediatrics (Weil Integrative Medicine Library).\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oxford University Press. 2010",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Kemper KJ. \"Mental Health Naturally.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        American Academy of Pediatrics. 2010",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Rosen L, Cohen J. \"Treatment Alternatives for Children.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ALPHA. 2012",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Internet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        The National Center for Complementary and Alternative Medicine National Institutes of Health",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <a href=\"file://nccam.nih.gov/\" target=\"_blank\">",
"         nccam.nih.gov",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        American Academy of Pediatrics, Section on Complementary and Integrative Medicine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <a href=\"file://www.aap.org/sections/chim/default.cfm\" target=\"_blank\">",
"         www.aap.org/sections/chim/default.cfm",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        The Canadian Pediatric CAM Network",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <a href=\"file://www.pedcam.ca\" target=\"_blank\">",
"         www.pedcam.ca",
"        </a>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12076=[""].join("\n");
var outline_f11_50_12076=null;
var title_f11_50_12077="IPS Hodgkin lymphoma";
var content_f11_50_12077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The International Prognostic Score for Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td colspan=\"3\">",
"        One point is given for each of the characteristics below present in the patient, for a total score ranging from zero to seven",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Serum albumin &lt;4 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Hemoglobin &lt;10.5 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Male gender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Age &gt;45 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Stage IV disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        White blood cell count &ge;15,000/microL",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\" colspan=\"3\">",
"        Absolute lymphocyte count &lt;600/microL and/or &lt;8 percent of the total white blood cell count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        When applied to an initial group of 5141 patients with advanced Hodgkin lymphoma treated prior to 1992 with combination chemotherapy with or without radiation therapy, five-year overall survival (OS) and freedom from progression (FFP) rates according to score were as follows",
"        <sup>",
"         [1]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Score",
"       </td>",
"       <td class=\"subtitle2\">",
"        Five-year FFP, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Five-year OS, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        89",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        77",
"       </td>",
"       <td class=\"centered\">",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        60",
"       </td>",
"       <td class=\"centered\">",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        51",
"       </td>",
"       <td class=\"centered\">",
"        61",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        5 or more",
"       </td>",
"       <td class=\"centered\">",
"        42",
"       </td>",
"       <td class=\"centered\">",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        When applied to 740 patients with advanced Hodgkin lymphoma treated with curative intent with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) from 1980 to 2010, five-year OS and FFP rates according to score were as follows",
"        <sup>",
"         [2]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Score",
"       </td>",
"       <td class=\"subtitle2\">",
"        Five-year FFP, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Five-year OS, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        88",
"       </td>",
"       <td class=\"centered\">",
"        98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        84",
"       </td>",
"       <td class=\"centered\">",
"        97",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        80",
"       </td>",
"       <td class=\"centered\">",
"        91",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        74",
"       </td>",
"       <td class=\"centered\">",
"        88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"       <td class=\"centered\">",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5 or more",
"       </td>",
"       <td class=\"centered\">",
"        62",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506.",
"      </li>",
"      <li>",
"       Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era. J Clin Oncol 2012; 30:3383.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12077=[""].join("\n");
var outline_f11_50_12077=null;
var title_f11_50_12078="Development human B cells";
var content_f11_50_12078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Development of human B cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 262px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stem cells develop into immature and mature B cells. Following appropriate activation, B lymphocytes rearrange their immunoglobulin genes to switch from IgM to IgG, IgA or IgE. B cells eventually differentiate into plasma cells which will produce various isotypes of antibodies. When developmental defects occur, immune deficiency such as common variable immune deficiency (CVID), selective IgM deficiency (sIgMD), and selective IgA deficiency (sIgAD) appear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12078=[""].join("\n");
var outline_f11_50_12078=null;
var title_f11_50_12079="Caffeine-halothane contracture test waveforms";
var content_f11_50_12079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Caffeine-halothane contracture test waveforms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 522px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Positive caffeine-halothane contracture test (CHCT). Each of the three muscle strips demonstrate a positive response to 3% halothane; contractile tension is greater than 0.7 g relative to baseline tension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henry Rosenberg, MD, with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_50_12079=[""].join("\n");
var outline_f11_50_12079=null;
